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ABSTRACT 
 
Immunity and inflammatory pathways are important in the genesis of cancers, including 
skin cancer. Functional genetic variation in immune and inflammatory modulators has 
the potential to affect disease predisposition. 
Amongst the different mediators of inflammation, the cyclooxygenases (COXs) evidently 
appear to be implicated in cancer. Scientific data suggested that COX-2 may play a role 
in different steps of cancer progression, by increasing proliferation of mutated cells, thus 
favoring tumor promotion as well as by affecting programmed cell death. COX-2 is a 
protein encoded by PTGS2 gene. 
Another gene that contributes to innate immunity and cell metabolism including 
inflammation, cell proliferation and migration, differentiation, apoptosis is the RNASEL 
which encodes a component of the interferon-regulated 2-5A system that functions in the 
antiviral and anti-proliferative roles of interferons. Several studies have identified 
variations in this gene associated with risk of different malignancies. 
Epigenetics also plays an important role in melanoma development and progression. 
Changes in methylation patterns of genomic DNA, histone modifications and microRNA 
expression can alter important cellular pathways. In particular, high expression of miR-
146a has been correlated with various cancers, including melanoma. Polymorphisms in 
the PTGS2 and RNASEL genes and in miR-146a associated with risk of various cancers, 
have been described. Previously, in our laboratory, the impact of PTGS2 gene 
polymorphism rs20417, RNASEL gene polymorphism rs486907 and miR-146a 
polymorphism rs2910164 was investigated in relation to the risk of predisposition to 
melanoma skin cancer. Combined genotypes of rs2910164C allele (miR-146a) together 
with rs486907A allele (RNASEL) and rs2910164C allele (miR-146a) together with 
rs20417GG genotype (PTGS2) showed a higher risk of melanoma only in the male 
population suggesting a sex-specific interaction between miR-146a and PTGS2 or 
RNASEL in their association with melanoma risk. 
Sex is a genetic factor involved in melanoma skin cancer, in particularly sex hormones 
can influence in development, survival, progression of this type of cancer. 
In the present study, we investigate if gene and protein expression of PTGS2/COX-2, 
RNASEL/RNase-L and miR-146a expression are differently affected by sex hormones 
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in skin cells. The effect of 17β-estradiol or testosterone in melanoma cells, keratinocyte 
cells and primary fibroblasts was analyzed. The eventuality miR-146a regulation upon 
PTGS2 or RNASEL 3’UTR genes expression was tested in keratinocyte cells. 
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SUMMARY/RIASSUNTO 
 
La pelle o cute è il rivestimento più esterno del corpo e l'organo più esteso dell'apparato 
tegumentario. La cute svolge diverse funzioni; quella più importante è la protezione del 
nostro organismo da ogni tipo di agente esterno. Le altre funzioni svolte dalla cute sono: 
la funzione sensoriale, la secrezione del sudore, la produzione di cheratina e di pigmenti 
come la melanina che ci protegge dai raggi ultravioletti, la regolazione della temperatura 
dell’organismo, la permeabilità che garantisce il bilancio idroelettrolitico e la funzione 
immunitaria. La pelle è costituita da una componente superficiale detta epidermide, e una 
più profondo detto derma, una sorta di impalcatura di sostegno irrorata da una fitta rete di 
vasi sanguigni. A separare queste due componenti vi è una sottile struttura detta 
membrana basale o giunzione dermo-epidermica. Nell’epidermide sono presenti diversi 
tipi di cellule: i cheratinociti, i melanociti, le cellule di Langerhans, le cellule di Merkel e 
rari linfociti T. In particolare, i cheratinociti e i melanociti sono le cellule della cute da cui 
possono derivare i tumori cutanei più frequenti. Nel derma e nell’ipodema sono presenti 
i fibroblasti. Sotto il derma, uno strato di grasso sottocutaneo e tessuto connettivo di vario 
spessore crea il terzo strato di pelle. Il melanoma maligno cutaneo (MM) è un tumore 
derivato dai melanociti epidermici attivati o geneticamente modificati; è quindi il risultato 
di complesse interazioni tra fattori genetici, costituzionali e ambientali. Associati alla 
predisposizione e alla progressione del melanoma vi sono numerosi geni ed interazioni 
geniche. In particolare, la partecipazione di geni che contribuiscono ai processi 
infiammatori è ampiamente riconosciuta in diversi tumori; incluso melanoma. Tra i 
differenti mediatori dell'infiammazione, le cicloossigenasi (COXs) sembrano 
chiaramente implicate nel cancro. Dati scientifici suggeriscono che la proteina COX-2 
può svolgere un ruolo in diverse fasi della progressione del cancro, aumentando la 
proliferazione delle cellule mutate, favorendo la promozione del tumore e influenzando 
la morte cellulare programmata. COX-2 è una proteina codificata dal gene PTGS2. Un 
altro gene che contribuisce all'immunità innata e al metabolismo cellulare tra cui 
infiammazione, proliferazione e migrazione cellulare, differenziazione e apoptosi, è il 
gene RNASEL che codifica un componente del sistema 2-5A regolato dall'interferone, il 
quale sistema ha funzioni antivirali e antiproliferative. 
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Anche l'epigenetica svolge un ruolo importante nello sviluppo e nella progressione del 
melanoma. I cambiamenti nei modelli di metilazione del DNA genomico, le 
modificazioni istoniche e l'espressione del microRNA possono alterare importanti vie 
cellulari. In particolare, un over-espressione di miR-146a è stata correlata a vari tipi di 
cancro, incluso il melanoma. 
Polimorfismi nei geni PTGS2 e RNASEL e nel miR-146a sono stati associati ad un 
maggiore rischio in vari tipi di cancro. Precedentemente, nel nostro laboratorio, è stata 
studiata l’influenza del polimorfismo rs20417 nel gene PTGS2, del polimorfismo 
rs486907 nel gene RNASEL e del polimorfismo rs2910164 del miR-146a associata al 
rischio alla predisposizione al melanoma. Più precisamente l’allele C dell’rs20417 nel 
gene PTGS2 e l’allele C dell’rs2910164 nel miR-146a possono rappresentare un fattore 
di rischio con un effetto additivo nella predisposizione al melanoma, ma solo nella 
popolazione maschile. Successivamente è stato eseguito uno studio di associazione tra 
genotipi dello SNP rs2910164 (miR-146a) combinato con lo SNP rs486907 (RNASEL), 
e lo SNP rs2910164 (miR-146a) combinato con lo SNP rs20417 (PTGS2). Ambedue le 
associazioni di polimorfismi hanno mostrato presentare un maggior rischio alla 
predisposizione del melanoma, (rs2910164 allele C vs rs20417 genotipo GG e rs2910164 
allele C vs rs486907 allele A) ma solo nella popolazione maschile. Tale dato suggerisce 
un'interazione sessuale specifica tra miR-146a e PTGS2 o RNASEL nella loro 
associazione con il rischio di melanoma. 
Il sesso è un fattore genetico coinvolto nel melanoma del cancro della pelle, in particolare 
gli ormoni sessuali possono influenzare lo sviluppo, la sopravvivenza, la progressione di 
questo tipo di cancro. 
Nel presente studio, verifichiamo se l'espressione genica e proteica di PTGS2/COX-2, 
RNASEL/RNase-L e dell’espressione del miR-146a, sono influenzate in modo differente 
dagli ormoni sessuali. L’effetto del 17β-estradiolo e del testosterone è stato analizzato in 
cellule di melanoma, in cheratinociti e in cellule di fibroblasti primari. Successivamente, 
l'eventuale regolazione del miR-146a sull'espressione dei geni PTGS2 o RNASEL è stata 
valutata nei cheratinociti. 
7  
 
 
INDEX 
ABSTRACT  .................................................................................................................... 3 
SUMMARY/RIASSUNTO  ............................................................................................ 5 
INDEX .............................................................................................................................. 7 
FIGURES LIST ............................................................................................................. 10 
TABLES LIST ............................................................................................................... 12 
ABBREVIATIONS ....................................................................................................... 13 
1 INTRODUCTION .................................................................................................. 19 
1.1 Cutaneous melanoma ........................................................................................ 19 
1.1.1 Type of melanoma/histology ..................................................................... 19 
1.1.2 Non melanoma skin cancer ....................................................................... 20 
1.1.3 Cutaneous Melanoma ................................................................................ 20 
1.1.4 Staging Melanoma ..................................................................................... 20 
1.1.5 Etiology ..................................................................................................... 21 
1.1.6 Exogenous factor ....................................................................................... 21 
1.1.7 Endogenous factor ..................................................................................... 22 
1.1.8 Incidence ................................................................................................... 22 
1.1.9 Sex-linked physiologic differences in skin ............................................... 23 
1.1.10 Sex differences in melanoma .................................................................... 24 
1.2 The skin ............................................................................................................ 24 
1.3 Inflammation and cancer .................................................................................. 26 
1.3.1 Inflammatory and tumor initiation ............................................................ 26 
1.3.2 Inflammatory and tumor promotion .......................................................... 26 
1.3.3 Inflammatory and tumor progression ........................................................ 27 
1.4 Cyclooxygenases (COXs family) ..................................................................... 28 
8 
 
1.4.1 PTGS2 gene regulation ............................................................................. 30 
1.4.2 PTGS2 polymorphism –765G/C ............................................................... 31 
1.5 2’-5’-Oligoadenylate Synthetase and RNase-L System ................................... 32 
1.5.1 Biochemical Properties of RNase-L .......................................................... 32 
1.5.2 Regulation of RNase-L Activity ................................................................ 33 
1.5.3 RNASEL polymorphism -1385G/A .......................................................... 34 
1.6 MicroRNA ........................................................................................................ 34 
1.6.1 Biogenesis ................................................................................................. 35 
1.6.2 The canonical pathway .............................................................................. 36 
1.6.3 Non canonical pathway ............................................................................. 37 
1.6.4 Mechanism of miRNA mediated gene regulation .................................... 37 
1.6.5 Action of miRNA ...................................................................................... 37 
1.6.6 miR-146 family ......................................................................................... 38 
1.6.7 miR-146a in innate immunity .................................................................... 39 
1.6.8 miR-146a in adaptive immunity ................................................................ 39 
1.6.9 miR-146a polymorphism rs2910164 G/C ................................................. 40 
2 MATERIAL AND METHODS ............................................................................. 42 
2.1 Cells culture ...................................................................................................... 42 
2.2 Sex hormones treatment for genes expression .................................................. 42 
2.3 Sex hormones treatment ................................................................................... 42 
2.4 RNA extraction and cDNA syntheses .............................................................. 43 
2.5 Quantitative real-time PCR (qRT-PCR) ........................................................... 43 
2.5.1 Reference gene evaluation ......................................................................... 44 
2.6 Statistical analysis ............................................................................................. 46 
2.7 Plasmid constructs ............................................................................................ 46 
9 
 
2.8 Transfections ..................................................................................................... 48 
2.8.1 MicroRNAs transfection ........................................................................... 48 
2.8.2 Determination of Inhibitor concentration .................................................. 48 
2.8.3 Plasmid transfections ................................................................................. 49 
2.9 Western blotting ................................................................................................ 49 
3 RESULTS ............................................................................................................... 51 
3.1 Quantitative real-time PCR (qRT-PCR) ........................................................... 51 
3.1.1 Candidate reference genes expression ....................................................... 51 
3.1.2 Gene stability ............................................................................................. 52 
3.1.3 Candidate RGs final ranking ..................................................................... 55 
3.2 miR-146a and PTGS2 RNASEL genes expression .......................................... 56 
3.3 Sex hormones treatment and gene expression assay ........................................ 57 
3.4 Real Time expression analyses after hormones treatments ............................. 59 
3.5 Western blotting analyses after hormones treatments...................................... 60 
3.6 Effects of miR-146a transfection upon PTGS2 and RNASEL expression. ..... 62 
3.7 Inhibitor concentration effects upon miR-146a expression ............................. 63 
3.8 Effect of miR-146a on reporter protein activity ............................................... 64 
3.9 Direct interaction of miR-146a with the RNASEL 3’UTR ............................. 65 
4 DISCUSSION ......................................................................................................... 67 
5 BIBLIOGRAPHY .................................................................................................. 72 
10  
FIGURES LIST 
 
Figure 1. Structure of the skin and the epidermis 
Figure 2. Prostaglandin E2 biosynthesis and downstream cellular effects 
Figure 3. MicroRNA biogenesis and mechanism of action. 
Figure 4. Mature form of miR-146a and miR-146b 
Figure 5a/b. pLightSwitch plasmid used for the construction of a plasmid containing a 
part of the 3’UTR of the PTGS2. b) PGL3 promoter vector used for the construction of a 
plasmid containing a part the 3’UTR of the RNASEL. 
Figure 6. Box-plot of the quantification cycle (Ct) values for each mRNA and miRNA 
candidate reference gene 
Figure 7. Comprehensive geometric mean of the ranking values of mRNA and miRNA 
candidate reference genes. 
Figure 8. Basal genes and mir-146a expression in Fibroblast, HaCaT and Melanoma 
cells. 
Figure 9. Effect of different concentration of sexual hormones upon PTGS2 and 
RNASEL genes expression. 
Figure 10. PTGS2 and RNASEL genes expression with 1 µM of testosterone and 500nM 
of estradiol at different hours. 
Figure 11. Expression of PTGS2, RNASEL and miR-146a after sex hormones treatment 
in the three cultured cells. 
Figure 12. Expression in western blotting of COX-2, RNase-L after sex hormones 
treatment in the three cultured cells. 
Figure 13. Effect of 50nM of exogenous miR-146a upon the expression of PTGS2 and 
RNASEL in HaCaT, melanoma and fibroblast cells. 
Figure 14.a/b/c PTGS2 and RNASEL miR-146a expression after different 
concentrations of inhibitor. 
Figure 15. Luciferase assay. Transfection of different plasmids in HaCaT cells. 
11  
Figure 16. Luciferase activity after different plasmid transfection in HaCaT cells. 
  
12  
TABLES LIST 
 
Table 1a/b. a) Primers used for the analysis of mRNA expression. b) Probe used for the 
analysis of miR expression. 
Table 2a/b. a) Primers used for the analysis of candidate mRNA reference genes. b) 
Probes used for the analysis of candidate miRNA reference genes. 
Table 3. Primer used for the genomic amplification and mutagenesis of plasmids 
containing the 3’UTR of PTGS2 and RNASEL. 
Table 4. Function of the Reference gene analyzed in this study. 
 
Table 5. Stability ranking of mRNA RGs analyzed by ΔCt, geNorm and Best-Keeper. 
13  
ABBREVIATIONS 
 
ABCE1: ATP Binding Cassette Subfamily E Member 1 
AGO: Argonaute 
AICD: Activation-induced cell death 
AKT: Serine/Threonine Kinase 
AP: Activator protein 
AR: Androgen Receptor 
ARD: Ankyrin repeat domain 
AREBPs: ARE-binding proteins 
AREs: Adenylate-uridylate-rich elements 
ATP: Adenosine triphosphate 
BCC: Basal cell carcinoma 
BRAF: B-Raf Proto-Oncogene 
CDK4: Cyclin Dependent Kinase 
CDKN2A: Cyclin Dependent Kinase Inhibitor 2A 
cDNA: Complementary DNA 
CM: Cutaneous melanoma 
 
c-MYB: MYB Proto-Oncogene 
COX-1: Cyclooxygenase-1 
COX-2: Cyclooxygenase-2 
COXIBS: COXs inhibitors 
CPSF: Cleavage polyadenylation specificity factor 
 
CRE: Cyclic monophosphate response element 
14  
DCs: Dendritic cells 
DGCR8: DiGeorge Syndrome Critical Region 8 
DMEM: Dulbecco’s modified Eagle’s medium 
DNA: Deoxyribonucleic Acid 
dsRNA: Double-stranded RNA 
 
EGFR: Epidermal growth factor receptor 
EP1: Prostaglandin receptor 1 
EP2: Prostaglandin receptor 2 
EP3: Prostaglandin receptor 3 
EP4: Prostaglandin receptor 4 
eRF3: Eukaryotic release factor 3 
ERs: Estrogen receptors 
ERα: Estrogen receptor alfa 
ERβ: Estrogen receptor beta 
FADD: Fas-associated death domain 
FBS: Fetal bovine serum 
GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase 
GOI: Gene of interest 
HaCaT: Human keratinocyte 
HKG: Housekeeping gene 
HPRT1: Hypoxanthine Phosphoribosyl transferase 1 
 
HRP: Horseradish peroxidase 
 
HSD11B1: Hydroxysteroid 11-Beta Dehydrogenase 1 
IFN: Interferon 
15  
IFN-γ: Interferon gamma 
IgG: Immunoglobulin G 
IgM: Immunoglobulin M 
IL-1: Interleukin-1 
IL-12: Interleukin-12 
 
IL1R1: Interleukin 1 receptor 
IL-1β Interleukin-1 beta 
IL-2: Interleukin-2 
IL-6: Interleukin-6 
IQGAP1: IQ Motif Containing GTPase Activating Protein 1 
IRAK: Receptor Associated Kinase 
KO: Knock-out 
 
LCs: Langerhans cells 
 
MAPK: Mitogen-activated protein kinase 
miRISC: miRNA-induced silencing complex 
miRNA: microRNA 
MM: Malignant melanoma 
 
MMP-2: Matrix metalloproteinase-2 
MMP-9: Matrix metalloproteinase-9 
16  
MREs: microRNA recognition elements 
mRNA: Messenger ribonucleic acid 
NF-IL6: Nuclear factor interleukin-6 
NF-κB: Nuclear Factor Kappa B  
NK Cells: Natural killer Cells 
NMSC: Non-melanoma skin cancer 
NRAS: NRAS Proto-Oncogene 
NSAIDS: Nonsteroidal anti-inflammatory drugs 
OAS: Oligoadenylate synthetase 
PABP: Poly (A)-binding protein 
PBS: Phosphate buffered saline 
Pca: Prostate carcinogenesis 
PEA3: Polyoma enhancer activator 3 
PGE2: Prostaglandin E2 
PGs: Prostaglandins 
 
PI3K: Phosphoinositide 3-kinase 
POLR2K: RNA Polymerase II Subunit K 
PPIA: Peptidylprolyl Isomerase A 
pre-miRNAs: Precursor miRNAs 
pri-miRNAs: Primary miRNAs 
PTGS2: Prostaglandin-endoperoxide synthase 2 
PVDF: Polyvinylidene Difluoride 
17  
qRT-PCR: Quantitative real-time PCR 
RanGTP: RAs-related NuclearGTP 
RG: Reference Gene 
RLI: RNase-L inhibitor 
RNA: RiboNucleic Acid 
RNase III: Ribonuclease III 
RNASEL / RNase-L: Ribonuclease L 
RNI: Reactive Nitrogen Intermediates 
ROS: Reactive Oxygen Species 
RPMI: Roswell Park Memorial Institute 
SCC: Squamous cell carcinoma 
SDS: Sodium dodecyl sulfate 
shRNA: Short hairpin RNA 
SNP: Single nucleotide polymorphism 
 
STAT1: Signal transducer and activator of transcription 1 
STAT3 Signal transducer and activator of transcription 3 
STDEV: Standard deviation 
TBP: TATA-Box Binding Protein 
TBS: TRIS buffered saline 
TCR: T cell receptor 
 
TGFβ: Transforming growth factor β 
Th1: T helper cells 1 
Th2: T helper cells 2 
 
TLR2: Toll Like Receptor 2 
18  
TLR4: Toll-like receptor 4 
TNF-α: Tumor necrosis factor-alfa 
Treg cells: Regulatory T cells 
USEs: Upstream enhancer elements 
UTR: Untranslated region 
UV: Ultraviolet 
 
VEGF: Vascular endothelial growth factor 
XPO5: Exportin-5 
YES1: YES Proto-Oncogene 1 
19  
1 INTRODUCTION 
 
1.1 Cutaneous melanoma 
 
Cutaneous malignant melanoma (MM) is a tumor derived from activated or genetically 
altered epidermal melanocytes, the result of complex interactions between genetic, 
constitutional, and environmental factors.1 
Melanocytes arise from the neural crest (pluripotent cells that give rise to neurons, glial 
cells, adrenal medulla, cardiac cells and craniofacial tissue) during embryonic 
development, and throughout their maturation migrate widely and proliferate extensively 
prior to their terminal differentiation and entry into the epidermis and hair follicle. In 
addition, melanocytes undergo multiple cycles of regeneration, in which melanocyte stem 
cells give rise to new populations of melanocytes.2 
In the skin, melanocytes are located in the basal layer of the epidermis. Melanocytes have 
a round shape with extensions named dendrites. Within the melanocytes are unique 
melanosomes organelles, which produce melanin. The melanosomes are transferred by 
the dendrites to the keratin layer where they are taken in by receptor- mediated 
endocytosis and deposited over keratin nucleus to protect the DNA from UV light. 
Keratinocytes secrete factors that regulate melanocytes survival, differentiation, 
proliferation and motility, stimulating the melanocytes to produce melanin and resulting 
in the tanning response.3 Also fibroblasts have a role in melanogenesis, and participate 
actively in the signal cross-talk between melanocytes and keratinocytes.4 
 
1.1.1 Type of melanoma/histology 
 
There are two main categories of skin cancer: non-melanoma skin cancer (NMSC) which 
originates in keratinocytes and pluripotent skin cells and cutaneous melanoma (CM) 
which originates from the transformation of melanocytes. Depending on the epidermal 
layer keratinocytes originate from, NMSC can be subdivided into basal cell carcinoma 
(BCC) and squamous cell carcinoma (SCC).5 
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1.1.2 Non melanoma skin cancer 
 
Basal Cell Carcinoma (BCC), also called basal cell epithelioma or rodent ulcer is the least 
aggressive type of skin cancer. This cancer develops from basal cells which line the 
deepest layer of the epidermis. An abnormal growth a tumor of this layer is what is 
referred to as BCC. It typically occurs in areas of chronic sun exposure such as the face, 
ears, neck, scalp and shoulders but can also develop on the back or lower legs. BCC is 
usually slow growing and very rarely metastasizes.  
Squamous Cell Carcinoma (SCC) begins in cells called keratinocytes, which are in the 
upper level of the epidermis. SCC most often develops in areas that have been exposed to 
the sun but can also develop in scars, areas of skin that have been burnt in the past and 
areas of skin that have been ulcerated for a long time. SCC is more aggressive than BCC 
as it has a faster growth rate, less well demarcated margins and greater metastatic 
potential.6 
 
1.1.3 Cutaneous Melanoma 
 
Cutaneous melanomas (CM) are the least common but most serious type of skin cancer. 
Although CM can occur anywhere in the body, including in the internal organs, this thesis 
only focuses on the experiences of those who have developed melanoma of the skin often 
referred to as cutaneous malignant melanoma. There are four basic types of melanoma 
which differ in frequency and location on the body. 
 
1.1.4 Staging Melanoma 
 
Accurate staging is vital for managing patients with cancer effectively. There were several 
methods for staging MM used in the 1980s and 1990s all of which have now been replaced 
by a single system developed from the existing American Joint Committee on Cancer 
(AJCC) staging system.7 This system was developed from data collected on more than 
17,000 patients and provides clearer, more accurate prognostic categories.8 The system is 
based on information about the primary tumor (T), the regional lymph node status (N) 
and the presence of distant metastases (M). Primary melanoma is divided into four 
groups, according to histological thickness: under one millimeter in thickness (Tl), 
between one and two millimeters (T2), between two and four millimeters (T3) and above 
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four millimeters (T4). Normal regional lymph nodes are designated as N0, whereas one 
involved node is designated as N1, two to four nodes as N2 and more than four nodes as 
N3. Metastases found in between the primary site and the regional nodes local or in transit 
metastases are included in the N category.  
Although individuals who develop distant metastases are likely to die from their disease, 
rates of progression vary between better prognosis skin and distant lymph node metastases 
(M1), and increasingly worse prognosis lung (M2), and liver and brain (M3) secondary.8 
 
1.1.5 Etiology 
 
As in most types of cancers, there are two sets of factors that present significant risk for 
melanoma in humans: endogenous and exogenous factors. 
The single most important exogenous factor is exposure to ultraviolet (UV) radiation9/10, 
traditionally equated with exposure to the sun but more recently also with artificial 
sources of UV radiation, such as sunbeds and sunlamps. The endogenous factors which 
include skin phototype (the amount of melanin pigment in the skin), number of moles, 
having atypical melanocytic naevi (unusual moles) and having a family history of skin 
cancer, are also important predictors of melanoma risk.11/12 
 
1.1.6 Exogenous factor 
 
Sun exposure is the main risk factor for malignant melanoma (MM). However, the UV- 
related pathogenetic mechanisms leading to MM are far to be fully elucidated.13 
The risk of melanoma appears to depend on the interaction between the nature of the sun 
exposure and the skin type. There is less evidence that sun exposure during adulthood 
contributes to the risk of MM. However, most of the evidence that the pattern of exposure 
is important relates to exposure in adulthood. Although different patterns of sun exposure 
are associated with different levels of risk for melanoma among individuals, it seems that 
intermittent sun exposure is associated with greater risk than total lifetime exposure.14/15 
Many clinical studies have reported that exposure to sunbeds or sunlamps has adverse 
effects on the skin and that their use might increase the risk of developing MM. 
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1.1.7 Endogenous factor 
 
The most important endogenous etiological factor of MM is the presence of both common 
acquired and atypical (dysplastic) melanocytic naevi (moles) and risk increases with the 
number of naevi.11 
People with very high numbers (100+) of common moles on their bodies have nearly 
seven times the risk compared to people with very few (0-15 moles).16 Furthermore, it has 
been seen that patients with a family history of melanoma are at increased risk. Around 
5-12% of patients with melanoma have a family history of MM in one or more first-degree 
relative.17 Some of these patients have inherited genes which are associated with a 
significantly increased risk of melanoma. To date, the major high-penetrance 
susceptibility genes that have been identified are CDKN2A (pi6), and CDK4. Overall, 
approximately 20%-40% of tested melanoma families showed inheritance of mutations 
in CDKN2A18, so far seventeen families have been found to have mutations in CDK4. 
The color of unexposed skin and the ability to tan, known as skin photo type are both 
factors linked to melanoma risk. 
 
1.1.8 Incidence 
 
The incidence of cutaneous melanoma continues to increase in the Caucasian population 
in the United States. In 2014, women only accounted for 42% of the 76,100 new 
melanoma cases and only 33% of the 9,710 deaths associated with CM in the United 
States.19 These trends are consistently observed in populations around the world.  Indeed, 
sex disparity in melanoma outcome is so repeatedly observed that gender has been 
suggested as an important prognostic factor, despite not being previously incorporated in 
staging algorithms.20 The source of this gender disparity in melanoma remains unclear, 
but likely represents both biological and behavioral etiologies. 
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1.1.9 Sex-linked physiologic differences in skin 
 
Skin is a dynamic, complex, integrated arrangement of cells, tissues, and matrix elements 
that mediates a diverse array of functions, including physical permeability barrier, 
protection from infectious agents, thermoregulation, sensation, ultraviolet (UV) 
protection, wound repair and regeneration. These various functions of skin are mediated 
by its major layers: the epidermis, dermis, and subcutaneous fat. 
The thickness of the skin is greater in men than in women at all ages.21/22 Skin thickness 
decreases in men and women starting at the age of 45, and women’s skin gets 10% thinner 
after menopause.23/24 These differences are likely modulated, in part, by hormones, given 
that they manifest during puberty and increase with age.25 
Women and men differ in the metabolism of and response to androgens and estrogens.26 
Estrogens are known to accelerate wound healing, improve inflammatory disorders, 
increase epidermal thickness, and protect against photo aging of the.27 The cellular effects 
of estrogens are mediated by estrogen receptors (ERs), ERα and ERβ, which belong to 
the nuclear steroid hormone receptor superfamily. ERα and ERβ are widely expressed in 
human tissue, but have differential distributions in various tissues, including the skin. 
ERα is primarily expressed in the uterus, liver, kidneys, breasts, and heart, whereas ERβ 
is primarily detected in what are known as non-classical estrogen- responsive tissues: the 
ovaries, colon, lungs, adipose tissue, prostate, bladder, and skin.28 Cutaneous ER levels 
are generally known to be higher in women as compared with men. However, relative 
levels of ERα and ERβ in men and women are not well understood. In women, the amount 
of ERs declines after menopause with declining levels of estradiol.28 In contrast to 
estrogens29, androgens such as testosterone and 5α- dihydroxy testosterone may be able 
to promote melanoma tumorigenesis. There are also several baseline differences in the 
immune systems of men and women. On average, women have higher measured IgG and 
IgM levels, as well as a greater percentage of CD3 + T lymphocytes, as compared with 
men, suggesting that men have a relative attenuation of the adaptive immune response 
compared with women.30 This is further evidenced by observations that men are more 
susceptible to bacterial and viral infections31, while women are more prone to 
autoimmune and inflammatory diseases.32 Men are also more prone to skin cancer; this 
increased risk may be partly explained by their heightened susceptibility to ultraviolet-
induced immunosuppression compared with women.33 Ultraviolet (UV) irradiation is 
known to inhibit contact hypersensitivity or delayed-type hypersensitivity. Also, sex 
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hormones may have an additional differential effect on immune cells.34 
 
1.1.10 Sex differences in melanoma 
 
Gender-specific differences in melanoma epidemiology are well established. The 
probability of developing melanoma during one’s lifetime is 1.72% in males and 1.22% 
in females.35 In the Netherlands, a large population-based cohort study including 10,538 
melanoma patients from 1993 to 2004 analyzed the gender difference in melanoma 
survival. The relative mortality risk excess was 2.70 (95% CI [2.38, 3.06]) in males versus 
females. 
The natural history of melanoma in women parallels the physiologic hormonal changes 
they undergo. The incidence of melanoma is rare before puberty, rises abruptly through 
the reproductive ages until approximately 50 years of age, and then diminishes after 
menopause.36 In agreement with the aforementioned survival advantages of young women 
and women with localized melanoma, women who present with stage IV  disease also 
show higher survival rates compared to men, who have a two-fold greater death rate from 
melanoma.37/38 It also reported that premenopausal women show a higher survival rate 
compared to postmenopausal women, which was more pronounced in women with 
advanced disease. Although the survival advantage decreases with age, postmenopausal 
women still have better rates of survival compared with men. 
 
1.2 The skin 
 
The skin forms a physical, chemical and immunological barrier of the organism towards 
the environment, preventing the invasion of pathogens, protecting from trans-epithelial 
water loss and regulating body temperature. Human skin consists of three major layers, 
the epidermis, the dermis and the underlying subcutaneous fat tissue (Figure 1). 
The epidermis consists mainly of keratinocytes which create the outermost barrier of the 
skin in a structure of multiple layers (Figure 1). From bottom to top, these histologically 
distinct epidermal layers are termed stratum basale, stratum spinosum, stratum 
granulosum, stratum lucidum and stratum corneum. Keratinocytes in the stratum basale 
proliferate constantly and migrate upwards, thus forming the different epidermal layers. 
During this process, the keratinocytes differentiate in various stages until they finally die 
and shed off. Keratinocytes are thus forming the physical barrier of the skin, but more 
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than that they are also important players in the immune surveillance of the skin by actively 
recognizing invading pathogens.39 
Besides keratinocytes, the epidermis also contains Langerhans cells, which are epidermis 
specific antigen-presenting dendritic cells that capture and present foreign antigens 
towards cells of the adaptive immune system.40 The basal layer of the epidermis also 
contains a population of melanocytes that produce melanin, a pigment that protects the 
organism from damages by UV irradiation 41, as well as Merkel cells, which sense tactile 
sensation.42 
Below the epidermis is the dermis, which is characterized by collagen- and elastin-rich 
connective tissue. The extensive extracellular matrix in the dermis creates stability and 
flexibility of the skin and is majorly produced by fibroblasts. The dermis contains blood 
vessels, hair follicles, sweat glands and sebaceous glands. The hair follicle does not  only 
produce hair, but serves also as a niche for epidermal stem cells.43 The dermis  hosts a 
large number and variety of immune cells, among them macrophages, dendritic cells, T 
and B cells, and NK cells, which generally provide additional immune surveillance, 
memory of previous infections and a quick primary immune response against invading 
pathogens. It has been estimated that skin resident T cells outnumber T cells in the 
circulation by two to one44, highlighting the importance of immune cells within the skin. 
Under the dermis, a layer of subcutaneous fat and connective tissue in varying thickness 
creates the third layer of the skin. 
 
  
 
Figure 1: Structure of the skin (left) and the epidermis (right). Illustration from the National Cancer 
Institute and the Wikiversity Journal of Medicine. 
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1.3 Inflammation and cancer 
 
Cancer results from the outgrowth of a clonal population of cells from tissue. The 
development of cancer, called to as carcinogenesis, requires the acquisition of six crucial 
properties: self-sufficient proliferation, insensitivity to anti-proliferative signals, evasion 
of apoptosis, unlimited replicative potential, the maintenance of vascularization, and, for 
malignancy, tissue invasion and metastasis.45 Cancer can also be considered with regard 
to a step-wise development functionally grouped into three phases: initiation, promotion, 
and progression.46 
 
1.3.1 Inflammatory and tumor initiation 
 
Tumor initiation is a process in which normal cells acquire the first mutational hit that 
sends them on the tumorigenic track by providing growth and survival advantages over 
their neighbors. In most cases, a single mutation is insufficient and many cancers require 
at least four or five mutations.47/45 It is also certain that each mutation be transmitted to 
the cell's progeny, and in cancers that arise within rapidly renewed epithelia (intestinal 
and skin cancers), oncogenic mutations must occur in either long- lived stem cells or 
transient amplifying cells rather than within differentiated cells, which are quickly 
eliminated before the next mutation can strike. Alternatively, oncogenic mutations can 
occur within differentiated epithelial cells, such as hepatocytes, which are capable of 
proliferation and are fairly long lived to allow subsequent mutational hits. 
It has been seen that an inflammatory microenvironment can increase mutation rates, in 
addition to enhancing the proliferation of mutated cells. In fact, Reactive Oxygen Species 
(ROS) and Reactive Nitrogen Intermediates (RNI) produced by inflammatory cells may 
cause mutations in neighboring epithelial cells. Also, cytokines produced by 
inflammatory cells can elevate intracellular ROS and RNI in premalignant cells. In 
addition, inflammation can result in epigenetic changes that help tumor initiation. Tumor-
associated inflammation contributes to further ROS, RNI, and cytokine production.48 
 
1.3.2 Inflammatory and tumor promotion 
 
Tumor promotion is the action of tumor growth from a single initiated cell into a 
completely developed primary tumor. Initial tumor growth depends on increased cell 
proliferation and reduced cell death, both of which are stimulated by inflammation- driven 
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mechanisms. Indeed, many of the enhancing effects of inflammation on cancer are exerted 
at the level of tumor promotion, and most known tumor promoters, for instance phorbol 
esters, are potent inducers of inflammation.49 Inflammation-induced tumor promotion 
may occur early or late in tumor development and can lead to activation of premalignant 
lesions that were dormant for many years. The mechanisms through which inflammation 
affects tumor promotion are numerous and, in addition to increased proliferation and 
enhanced survival, can also involve the so-called angiogenic switch, which allows a small 
dormant tumor to receive the blood necessary for the next growth phase.50 
For example, the cytokines produced by tumor-infiltrating immune cells activate key 
transcription factors, such as NF-κB or STAT3, in premalignant cells to control numerous 
pro-tumorigenic processes, including survival, proliferation, growth, angiogenesis, and 
invasion. As elements of positive feed-forward loops, NF-κB and STAT3 induce 
production of chemokines that attract further immune/inflammatory cells to assist tumor-
associated inflammation.48 
 
1.3.3 Inflammatory and tumor progression 
 
Metastasis is the most critical aspect of tumorigenesis, because over 90% of cancer 
mortality is caused by metastasis. Recent studies unambiguously show that metastasis 
requires close collaboration between cancer cells, immune and inflammatory cells, and 
stromal elements. The process of metastasis can be grossly divided into four major steps. 
In the first step, cancer cells acquire fibroblastoid characteristics that increase their 
motility and allow them to invade epithelial linings/basal membranes and reach efferent 
blood vessels or lymphatics.51 Loss of E-cadherin expression is envisioned as a key event 
in the epithelial-mesenchymal transition. In the second phases, cancer cells intravasate 
into blood vessels and lymphatics.48 Inflammation may promote this through production 
of mediators that increase vascular permeability. This is followed by the third phases, in 
which metastasis-initiating cells survive and travel throughout the circulation.48 Next, 
integrin-mediated arrest allows the extravasation of circulating cancer cells. Finally, 
single metastatic progenitors interact with immune, inflammatory, and stromal cells and 
start to proliferate.52 One of these inflammatory signals is the extracellular matrix 
component versican, which leads to macrophage activation and production of the 
metastasis-promoting cytokine TNF-α.53 
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1.4 Cyclooxygenases (COXs family) 
 
Cyclooxygenases are enzymes necessary for the metabolic conversion of arachidonic acid 
to prostaglandins, including PGE2, a major mediator of inflammation and angiogenesis 
(Figure 2). PGE2 signals through four pharmacologically distinct G- protein coupled 
receptors, EP1, EP2, EP3, and EP4, which each activate different downstream signaling 
pathways.54 In turn, PGE2 is catabolized to the inactive 15-keto- PGE2 by the enzyme 15-
hydroxyprostaglandin dehydrogenase.55/56 There are two isoforms of cyclooxygenase: 
COX-1 and COX-2. Both exist as integral, membrane- bound proteins, located primarily 
on the luminal side of the endoplasmic reticulum and nuclear envelope.55 COX-1 is 
characterized as a housekeeping enzyme required for the maintenance of basal level 
prostaglandins57 and is expressed constitutively in most tissues. It is responsible for the 
maintenance of internal homeostasis by participating in processes such as platelet 
aggregation, cytoprotection of the gastric mucosa, vascular smooth muscle functioning, 
and renal function. In contraposition, COX-2 usually remains undetected in healthy 
tissues and organs. In adults, it is found only in the central nervous system, kidneys, 
vesicles, and placenta, whereas in the fetus, it occurs in the heart, kidneys, lungs, and 
skin.55/58 COX-2 is highly inducible and can be rapidly upregulated in response to various 
proinflammatory agents, including cytokines, mitogens, and tumor promoters, especially 
in cells involved in inflammation, pain, fever, Alzheimer's disease, osteoarthritis, or 
tumor formation.55/59 Under normal conditions, acute inflammation is a tightly controlled 
self-limiting response, where upon abatement of the inflammatory stimulus, specific 
cytokines, including interleukin-1 (IL-1) and interleukin-6 (IL-6), exert feedback 
inhibition causing COX-2 expression and PGE2 production to cease and the inflammatory 
response to subside.60 However, with sustained exposure to proinflammatory stimuli, 
continued expression of COX-2 leads to the transition from acute to chronic 
inflammation.55/60 In recent decades, COX-2 overexpression has been reported in several 
human cancers including breast61/62, lung61/63, skin64, colon63/65/66, bone67/68/69, cervical70, 
esophageal71, pancreatic72, prostate73 and bladder cancer.74 Constitutive expression of 
COX-2 and sustained biogenesis of PGE2 appear to play predominant roles in the 
initiation and promotion of cancer progression. PGE2 can mediate these effects through 
numerous signaling pathways including activation of vascular endothelial growth factor 
(VEGF) leading to increased cell proliferation, metastatic and invasive potential, and 
angiogenesis75/76; increased expression of the protooncogenes, and the epidermal growth 
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factor receptor (EGFR), through the activation of the mitogen-activated protein kinase 
(MAPK) and the phosphoinositide 3- kinase (PI3K)/AKT pathway, respectively77/78; 
increased transcriptional activity of the antiapoptotic mediator nuclear factor κB (NF-
κB)79; enhanced metastasis and invasion by activation of matrix metalloproteases (MMP-
2 and MMP-9)80 and suppression of the production of IL-12, leading to 
immunosuppression.81 Therefore, COX-2 and the prostaglandin cascade play important 
roles in the “inflammogenesis of cancer”.82 
 
 
 
 
 
Figure 2: Prostaglandin E2 biosynthesis and downstream cellular effects. Arachidonic acid is released 
from cellular membranes and converted to PGH2 through the activity of the COX enzymes. COX-1 is 
constitutively expressed in many cells, generating low levels of prostaglandins that are cytoprotective and 
maintain homeostasis. In contrast, COX-2 is absent from most cells and is induced by a number of 
inflammatory stimuli. PGH2 is rapidly converted to PGE2, which plays a predominant role in cancer 
progression by stimulating tumor cell proliferation, migration, angiogenesis, apoptosis resistance, 
invasion, and metastasis. NSAIDS and COXIBS can pharmacologically block the activity of the COX 
enzymes. 
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1.4.1 PTGS2 gene regulation 
 
The PTGS2 gene (also named COX2) maps to chromosome 1(1q25.2-25.3), contains 10 
exons and codes for a protein of 604 aa: the inducible cyclooxygenase Cox-2 
(http://www.genecards.org/cgi-bin/carddisp.pl?gene=PTGS2). PTGS2 is an immediate- 
early response gene whose expression is highly induced in response to hormones, 
proinflammatory cytokines, growth factors, oncogenes, carcinogens and tumor 
promoters.83/84 
PTGS2 expression is regulated at both transcriptional and post transcriptional level, and 
the deregulation of PTGS2 expression observed in carcinogenesis can in part be due to 
functional changes affecting these regulatory regions of the gene. 
The promoter region of the PTGS2 gene contains several key cis-acting regulatory 
elements, including a canonical TATA box, and various response elements for nuclear 
factor kB (NK-kB), PEA3, AP2, nuclear factor interleukin-6 (NF-IL6), Sp1, adenosine 
3’, 5’-cyclic-monophosphate-response element (CRE), c-MYB, transforming growth 
factor β (TGFβ), and others. Depending on the stimulus and the cell type, these 
transcription factors can play a decisive role in the regulation of COX-2 
transcription.85/86/87/88 
Current studies have demonstrated that post-transcriptional regulation plays a central role 
in the regulatory mechanisms of PTGS2 expression.89 The PTGS2 3′UTR is larger than 
average, encompassing ~2.5 kb, and has many interesting features. It has several 
polyadenylation signals, only two of which are commonly used, resulting in mRNAs of 
~2.8 or ~4.6 kb. The proximal polyadenylation signal has a non-consensus CPSF 
(cleavage polyadenylation specificity factor) binding site (AUUAAA), followed by 
putative upstream enhancer elements (USEs). It is likely that regulation occurs in part 
here, resulting in two mRNAs with different RNA metabolism. The significance of the 
different tissue distributions of these isoforms has not yet been addressed, and tissue 
specificity might play a role in PTGS2 polyadenylation site choice.90 The 3′UTR also has 
22 repeats of adenylate and uridylate-rich (AU-rich) elements (AREs), composed of the 
sequence 5’-AUUUA-3. This AU-rich region is highly conserved in both sequence and 
location among human, mouse, rat, chicken, pig, cow and sheep PTGS2 mRNA transcript, 
implying that the function of the ARE have been evolutionary conserved. This element, 
which is present within the 3'UTRs of many proto-oncogene and cytokine mRNAs, 
confers post-transcriptional control of expression. There are many different polypeptides 
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that specifically interact with AREs from rapidly degraded mRNAs. These regulatory 
trans-acting factors include several cytoplasmic mRNA-binding proteins proposed to be 
involved with the destabilization, stabilization, or mRNA processing and 
nucleocytoplasmic transport.90/86/91 Regulation of gene expression at a post- 
transcriptional level is also mediated by microRNAs, short single-stranded non-coding 
RNAs, which affect stability and translation of their target mRNAs.92 
In particular, PTGS2 contains a putative binding for miR-146a and it has been 
demonstrated that miR-146a directly regulates PTGS2 mRNA expression in lung cancer 
cells and in gastric epithelial cell lines.93/94 
 
1.4.2 PTGS2 polymorphism –765G/C 
 
One of the common polymorphisms present in the promoter region of the PTGS2 gene (-
765G/C) has been reported to alter promoter activity.95/96 Polymorphism -765G/C 
(rs20417) is located at a putative Sp1 binding site and it has been shown that allele - 765C 
have significantly lower promoter activity compared with -765G in human lung 
fibroblasts cells. This polymorphism has been associated to myocardial infarction and 
stroke, to asthma risk, and to the risk of esophageal cancer. 95/96/97 However, it has also 
been reported that production of PG by monocytes of asthmatic patients is more than ten-
fold higher in –765CC homozygotes, than in –765GG homozygotes.98 These opposite 
results could be explained by a tissue specific effect of this polymorphism; - 765G can 
potentially eliminate an Sp1 binding site, but can also generate a binding site for E2F, a 
cyclin-dependent regulator of expression of several genes, including PTGS2.98/99 
 
A case/control study, by Gomez-Lira M.100 et al 2014, showed that the -765C allele is 
more represented in patients than in controls. Frequency of this polymorphism indicated 
that allele -765C may be associated with a higher risk of MM. Expression analysis of the 
PTGS2 gene in the same study, showed that allele -765C is associated with a higher gene 
expression and could represent a risk allele by affecting the functionality of the promoter. 
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1.5 2’-5’-Oligoadenylate Synthetase and RNase-L System 
 
RNase-L is a cellular endoribonuclease which is involved in degrading viral and cellular 
RNA as an antiviral mechanism.101/102 RNase-L together with 2’-5’ oligoadenylate 
synthetase forms an important component of antiviral innate immune system. Viral 
dsRNA and interferon induce the expression of 2’-5’-oligoadenylate synthetase (OAS), 
which converts cellular ATP into a unique oligoadenylate 2’-5’ A, referred to hereafter 
as 2-5A.103/104 2-5A is a unique ligand that binds only RNase-L activating RNase-L. 
Human RNase-L is a 741 amino acid polypeptide with an N-terminal ankyrin repeat 
region and a C-terminal endoribonuclease domain. In the absence of 2-5A binding, the 
N-terminal ankyrin repeat region suppresses the ribonuclease domain. 2-5A binding 
induces a conformation changes allowing dimerization of inactive RNase-L monomers to 
form active dimers with potent ribonuclease activity.105/106 Active RNase-L cleaves both 
viral and cellular RNA blocking viral replication. RNase-L cleaves within single- 
stranded regions of RNA, principally on the 3’ sides of UpAp and UpUp dinucleotides, 
leaving 3’phosphoryl and 5’hydroxyl groups at the termini of the RNA cleavage 
products.101 
 
1.5.1 Biochemical Properties of RNase-L 
 
RNase-L is a regulated endoribonuclease constitutively expressed in every mammalian 
cell type. RNase-L consists of three major domains; an N-terminal regulatory ankyrin 
repeat domain (ARD), a middle protein kinase like domain, and a C-terminal ribonuclease 
domain (RNase).105/107 Ankyrin repeat domains (ARD) are conserved protein-protein 
interaction motifs composed of multiple α-helices connected by β- hairpin turn. RNase-L 
has 9 ankyrin repeats with 2 and 4 responsible for 2-5A binding.107 Recent crystal 
structure of RNase-L has further shown that RNase-L recognizes 2-5A through 
coordinated interactions involving the Ankyrin repeat domain and the pseudo-protein 
kinase domain, with an unexpected role of nucleotide binding to the pseudo-protein 
kinase domain, which facilitates the imposition of a specific dimer configuration required 
for RNase catalytic function.108 Binding of 2-5A to the ankyrin repeat is a unique feature 
of RNase-L. In the absence of 2-5A binding, ARD represses the RNase domain.107/109 2-
5A binding induces a conformation change which releases the RNase domain 
autoinhibition and unmasks the protein-protein interaction regions. The middle kinase-
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like domain provides contact for 2-5A and nucleotide which is responsible for 
dimerization after 2-5A binding.107/108 RNase-L lacks kinase activity due to the absence 
of phosphor acceptor sites required for an active kinase.102 The kinase- like domain has 
highly conserved residues responsible for ATP binding and stimulation of enzyme 
activity and mutations in those regions has been shown to impair RNase-L activity.110 
Two distinct mutants of RNase-L have been described; R667A, which is deficient in the 
ribonuclease activity, and R462Q, which is defective in dimerization, and has 3-fold 
decrease in RNase-L activity.111/112 
 
1.5.2 Regulation of RNase-L Activity 
 
Activation of RNase-L occurs by specific binding of trimer or higher oligomers of 2-5A 
to the N-terminal ankyrin repeats. 2-5A is a very unstable molecule and is degraded by a 
combination of 5’-phosphatase and 2’, 5’-phosphodiesterase presents in cells. Activity of 
RNase is negatively regulated by a cellular protein RNase-L inhibitor (RLI) also known 
as ABCE1. Overexpression of RLI inhibits 2-5A binding and ribonuclease activity of 
RNase-L.113 Expression of RLI is not regulated by interferons but can be induced by 
certain viruses and dsRNA.114 RNase-L is expressed in all mammalian cell types and 
subject to post-transcriptional regulation by the 3’-untranslated region (3’ UTR). RNase-
L expression is negatively regulated by microRNA miR-29 which has target sites in the 
3’-UTR in RNase-L mRNA. RNASEL contains a putative binding for miR-146a, but 
there are no scientific data concerning their relation. 
RNASEL 3’UTR also contains AU-rich elements (AREs) which are cis-acting regulatory 
regions that modulate mRNA stability through the binding of ARE-binding proteins 
(AREBPs). HuR is an ARE-binding protein that induces RNase-L expression during 
stress or myoblast differentiation. HuR and miR-29 therefore mediate antagonistic effects 
on RNase-L expression.115 RNase-L activity is also regulated by protein-protein 
interactions. In addition to RLI, mammalian RNase-L interacts with eukaryotic release 
factor 3 (eRF3), androgen receptor (AR), IQGAP1 and Filamin A.113/116 Interaction of 
RNase-L with eRF3 is 2-5A dependent and modulates translation in cells. In the presence 
of 2-5A, RNase-L interacts with eRF3 reducing the binding to poly (A)-binding protein 
(PABP) decreasing translation re-initiation and promoting translation. RNase-L interacts 
with the androgen receptor in the presence of androgens which is recruited to the promoter 
of AR responsive genes targeting them for IFN stimulated and specific degradation 
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downregulating AR signaling.116 Binding of RNase L to Filamin A forms a barrier in 
mammalian cells preventing the entry of virus.116 RNase L is shown to bind several actin-
binding proteins and has been shown to localize to the cytoskeletal fraction in cells.118 
 
1.5.3 RNASEL polymorphism -1385G/A 
 
A common missense mutation in RNASEL, R462Q (rs486907, G/A), has been studied 
extensively in genetic epidemiology studies.119/120/121 The homozygous genotype (AA) 
has 15% prevalence in Caucasian populations and causes a functionally significant amino 
acid substitution resulting in a 3-fold decrease in enzymatic activity. This variant could 
enhance virus susceptibility, decrease control of cellular RNA levels, impair the cellular 
stress response, or induce apoptosis.122 While under normal conditions RNASEL has 
tumor suppressive and anti-proliferative functions, RNASEL variants, including the 
common rs486907 variant, have been associated with risk of a number of cancers, i.e. 
prostate, colorectal and pancreatic cancer, and overall risk of cancer in individuals of 
African descent.123/122 
A case/control study by Gomez-Lira M124. et al 2017, evaluated the impact of RNASEL 
polymorphism rs486907 on melanoma risk, showing an association of this SNP to 
melanoma risk. 
 
1.6 MicroRNA 
 
miRNAs are small non-coding RNAs, with an average 22 nucleotides in length.125 Most 
miRNAs are transcribed from DNA sequences into primary miRNAs (pri-miRNAs) and 
processed into precursor miRNAs (pre-miRNAs) and mature miRNAs.125 In most cases, 
miRNAs interact with the 3′UTR of target mRNAs to suppress expression.126 However, 
interaction of miRNAs with other regions, including the 5′UTR, coding sequence, and 
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gene promoters, have also been reported.127 Furthermore, miRNAs have been shown to 
activate gene expression under certain conditions.128 Recent studies have suggested that 
miRNAs are shuttled between different subcellular compartments to control the rate of 
translation, and even transcription.129 Aberrant expression of miRNAs is associated with 
many human diseases.130/131 In addition, miRNAs are secreted into extracellular fluids. 
Extracellular miRNAs have been widely reported as potential biomarkers for a variety of 
diseases and they also serve as signaling molecules to mediate cell-cell 
communications.132/133 
 
1.6.1 Biogenesis 
 
miRNA biogenesis starts with the processing of RNA polymerase II/III transcripts post- 
or co-transcriptionally.125/126 About half of all currently identified miRNAs are intragenic 
and processed mostly from introns and relatively few exons of protein coding genes, while 
the remaining are intergenic, transcribed independently of a host gene and regulated by 
their own promoters.134/135 Sometimes miRNAs are transcribed as one long transcript 
called clusters, which may have similar seed regions, and in which case they are 
considered a family.136 The biogenesis of miRNAs is classified into canonical and non-
canonical pathways (Figure 3).
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Figure 3: MicroRNA biogenesis and mechanism of action. Modified from Hayder et al. 
 
 
 
1.6.2 The canonical pathway 
 
The canonical biogenesis pathway is the dominant pathway by which miRNAs are 
processed.125 In this pathway, pri-miRNAs are transcribed from their genes and then 
processed into pre-miRNAs by the microprocessor complex125, consisting of an RNA 
binding protein DiGeorge Syndrome Critical Region 8 (DGCR8) and a ribonuclease III 
enzyme, Drosha.137 DGCR8 recognizes an N6-methyladenylated GGAC and other motifs 
within the pri-miRNA138, while Drosha cleaves the pri-miRNA duplex at the base of the 
characteristic hairpin structure of pri-miRNA. This results in the formation of a 2 nt 3′ 
overhang on pre-miRNA. 125/139 Once pre-miRNAs are generated, they are exported to the 
cytoplasm by an exportin 5 (XPO5)/RanGTP complex and then processed by the RNase 
III endonuclease Dicer. 125/137/140 This processing involves the removal of the terminal 
loop, resulting in a mature miRNA duplex.141 The directionality of the miRNA strand 
determines the name of the mature miRNA form. The 5p strand arises from the 5′end 
of the pre-miRNA hairpin while the 3p strand originates from the 3′end. 125 Both strands 
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derived from the mature miRNA duplex can be loaded into the Argonaute (AGO) family 
of proteins (AGO1-4 in humans) in an ATP-dependent manner.141 
 
1.6.3 Non canonical pathway 
 
Non canonical pathways make use of different combinations of the proteins involved in 
the canonical pathway, mainly Drosha, Dicer, exportin 5, and AGO2.125 In general, the 
non-canonical miRNA biogenesis can be grouped into Drosha/DGCR8-independent and 
Dicer-independent pathways.125 Pre-miRNAs produced by the Drosha/DGCR8- 
independent pathway resemble Dicer substrates.125 These nascent RNAs are directly 
exported to the cytoplasm through exportin 1 without the need for Drosha cleavage. There 
is a strong 3p strand bias most likely due to the m7G cap preventing 5p strand loading 
into Argonaute.142 On the other hand, Dicer-independent miRNAs are processed by 
Drosha from endogenous short hairpin RNA (shRNA) transcripts. These pre- miRNAs 
require AGO2 to complete their maturation within the cytoplasm because they are of 
insufficient length to be Dicer-substrates.143 This in turn promotes loading of the entire 
pre-miRNA into AGO2 and AGO2-dependent slicing of the 3p strand. 125 The 3′- 5′ 
trimming of the 5p strand completes their maturation.144 
 
1.6.4 Mechanism of miRNA mediated gene regulation 
 
Most studies to date have shown that miRNAs bind to a specific sequence at the 3 ′UTR 
of their target mRNAs to induce translational repression and mRNA deadenylation and 
decapping.145/146 miRNA binding sites have also been detected in other mRNA regions 
including the 5′ UTR and coding region has been reported to induce transcription.147 
 
1.6.5 Action of miRNA 
 
MiRNA-mediated gene regulation is dynamic and helps to buffer gene expression to a 
steady state.125 It is only recently that a more comprehensive understanding of miRNA 
dynamics has begun to shed light on the highly robust nature of miRNA-mediated gene
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regulation.125 Factors that may contribute to the robustness of miRNA-mediated gene 
regulation include the functionalized compartmentalization and shuttling of miRISC 
within the cells.125 The availability and abundancy of miRNAs and their target mRNAs 
are also contributing factors in determining which genes are regulated. Although this is 
not always the case, miRNA suppression of mRNA targets is not ubiquitous between cell 
types.125 Alternative splicing and alternative polyadenylation affecting 3′UTRs, and cell 
type-specific RNA binding proteins that affect target mRNA secondary structures, change 
the available pool of MREs.148/149/150 
This renders subsets of mRNAs sensitive or insensitive to miRNA-mediated gene 
regulation in a cell type/state-specific manner. 125 
 
1.6.6 miR-146 family 
 
During the past several years some miRNA functions in the immune system have been 
unveiled, among which one miRNA has shown important regulatory functions: miR-146. 
The murine and the human genome contain two miR-146 genes: miR-146a and miR-
146b.151 Mir-146a and miR-146b are both conserved in all vertebrate and are involved in 
the regulation of inflammation and other processes in innate as well as adaptive immunity. 
Some miRNAs, like these two miR-146 molecules, are expressed as a family that share 
the same seed sequence but are encoded by different loci in the genome. MiR-146a and 
miR-146b are located on chromosome 5 and 10, respectively, and their products differ 
only by 2nt in the 3’ region, while the ‘seed’ sequence, that is a conserved heptamer 
situated in the miRNA 5 ́- end, is identical, implicating that both miR-146a and miR-146b 
should recognize the same targets (Figure 4). 
 
hsa-miR-146a 
hsa-miR-146b 
 
Figure 4: Mature form of miR-146a and miR-146b. The regions highlighted in red display the differences 
in sequence. Shaded in grey is the seed sequence, important for target recognition and identical in both 
miRNAs. 
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Most studies examined primarily miR-146a rather than miR-146b, since these two 
miRNAs should recognize the same targets, but miR-146a is often more abundantly 
expressed in the immune system. 
 
1.6.7 miR-146a in innate immunity 
 
The innate immune response is the first line of defense against invading pathogens and 
the primary initiator of inflammatory responses involving monocytes, macrophages, 
granulocytes, and various types of DCs (dendritic cells), including LCs (Langerhans 
cells). The central pathway in innate immunity is the NF-κB pathway, and it is targeted 
by a number of miRNAs, of which miR-146a was the first discovered to be involved. 
miR-146a itself is an NF-κB–dependent miRNA, and it targets the TLR4 signaling 
pathway through a negative feedback regulation loop that involves the downregulation of 
IL-1 receptor–associated kinase (IRAK) 1 and TNF receptor–associated factor 6.152 miR-
146a expression is higher in LCs compared with that seen in other DCs. It does not 
influence LC differentiation, but it desensitizes LCs to TLR2-dependent activation.153 In 
peripheral blood monocytes in mice and CD14+ monocytes in human subjects, miR- 146a 
controls monocyte responses during inflammatory challenge through a member of the 
noncanonical NF-κB/Rel family.154 
 
1.6.8 miR-146a in adaptive immunity 
 
Adaptive immunity is mediated mainly by T and B lymphocytes and involves recognition 
of specific molecules and selection and expansion of antigen-specific T- and B-cell 
clones. It provides the host with a learned memory that leads to secondary responses, 
mainly involved in chronic inflammatory processes, including development of 
autoimmunity and allergic diseases.155 
As for the role of miR-146a in T cells, by analyzing the expression of miRNAs in subsets 
of cells of the immune system, it has been show that miR-146a is one of the very few 
miRNAs differentially expressed between Th1 (T helper cells 1) and Th2 (T helper cells 
2) cells in the mouse, suggesting that it might be involved in the fate determination of 
these cells.156 In human T cells, miR-146a is expressed at low levels in naïve T 
lymphocytes while it is abundantly expressed in memory T cells and it is induced upon 
TCR (T cell receptor) stimulation, consistent with its expression being dependent on NF-
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κB induction.157/158 Treg cells constitute a specialized T-cell subset able to maintain 
immune homeostasis by limiting the inflammatory responses, and their suppressive 
function is indispensable for immune homeostasis and survival of higher organisms. 
Recently, Lu and colleagues159 reported that miR-146a is among the miRNAs prevalently 
expressed in Treg cells and showed that it is critical for Treg functions. Indeed, deficiency 
of miR-146a resulted in increased number but impaired function of Treg cells and as a 
consequence, breakdown of immunological tolerance. 
Overall, these data showed an important role for miR-146a in regulating both innate and 
adaptive immunity, and a dysregulation of miR-146a expression may lead to a number of 
diseases, including cancer. 
 
1.6.9 miR-146a polymorphism rs2910164 G/C 
 
An allelic polymorphism, the rs2910164 G/C single-nucleotide polymorphism, altering 
the amount of mature miR-146a has been described in the gene encoding for pre-
miR146a, the precursor molecule of miR-146a,160/161 but only relatively few studies have 
investigated its effect on the risk of cancer. Some studies suggested a possible relationship 
between the pre-miR-146a polymorphism and the risk of different tumor types.160/162/163 
while others have not found such a connection.163 This polymorphism is located in the 
seed region of pre‐miR‐146a‐3p sequence and leads to the formation of two different 
isoforms that can regulate distinct sets of genes.164 
Gomez-Lira165 et al 2015 notated that rs2910164 G/C SNP genotype distribution and 
allele frequency were different between cases (224 patients with MM) and controls (264), 
indicating an association of the polymorphism with the melanoma risk. 
These result are reinforced by a recent study showing that miR‐146a is regulated by 
BRAF and NRAS and plays an essential role in the initiation and progression of 
melanoma.166 Stratifying by gender, Gomez Lira165 et al 2015, observed that the 
association of the variant with melanoma was restricted to males. Gender‐specific 
association of this polymorphism with carcinogenesis has also been observed in several 
other studies.162/167 In 2017, Gomez Lira124 et al observed a sex-specific effect of the miR-
146a rs2910164C allele restricted to individuals carrying the RNASEL rs486907A allele. 
Recently, our group, (manuscript in preparation) analyzed the possible effect of the 
presence of the two polymorphisms (rs2910164G/C in miR-146a and rs20417G/C in the 
PTGS2 gene) with melanoma predisposition and observed that the risk effect of 
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rs2910164C allele was restricted to the subgroup of males carrying also the rs20417GG 
genotype. This is the first study that evaluates the impact of PTGS2 polymorphism 
rs20417 and miR-146a rs2910164 upon melanoma risk and defines that miR-146a 
rs2910164C risk allele is restricted to males carry rs20417GG genotype in the PTGS2 
gene, suggesting an interaction between the two genes. 
 
In the present study, in order to investigate if gene and/or protein expression of 
PTGS2/COX-2, RNASEL/RNase-L or miR-146a expression are differently affected by 
sex hormones in skin cells, we analyzed the effect of 17β-estradiol or testosterone in 
melanoma cells, keratinocyte cells and primary fibroblast. The eventuality miR-146a 
regulation upon PTGS2 or RNASEL 3’UTR genes expression was tested in keratinocyte 
cells. 
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2 MATERIAL AND METHODS 
 
 
 
2.1 Cells culture 
 
A melanoma cell line (LM-20), provided by Dr. Monica Rodolfo (Istituto Nazionale 
Tumori, Milan) was grown in Roswell Park Memorial Institute 1640 (RPMI 1640, Gibco, 
Life Technologies). Human keratinocyte cell line (HaCaT) was cultured in the Dulbecco’s 
modified Eagle’s medium (DMEM, Gibco, Life Technologies), primary fibroblasts 
cultures were purchased from Istituto Zooprofilattico Sperimentale, Brescia (Italy) and 
maintained in Advanced Dulbecco’s modified Eagle’s medium (DMEM, Gibco Life 
Technologies). Culture media were supplemented with 2 mM L-glutamine, 
penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively) and 10% (v/v) fetal 
bovine serum (FBS). All cell cultures were maintained in a humidified incubator at 37°C 
in 5% CO2. 
 
2.2 Sex hormones treatment for genes expression 
 
Fifty thousand (50.000) HaCaT cells were plated in 24-well plates. Cells were cultured in 
red phenol free medium supplemented with 10% charcoal treated serum, before and 
during the treatment. Sex hormones were added to cells at 1 µM, 10 nM and 0.1 nM for 
testosterone and 500 nM, 100 nM, 1 nM and 0.01 nM for 17β-estradiol, while only ethanol 
(0.00001% solvent) was added to the control group. After 24 hours, RealTime PCR 
(qPCR) for PTGS2 and RNASEL genes expression and cells viability were performed to 
choose the best concentration of both sex hormones. Cells viability was carried out using 
the method of Trypan blue exclusion. 
 
2.3 Sex hormones treatment 
 
Two hundred seventy thousand (270.000) melanoma, HaCaT and primary fibroblast cells 
were plated in 6-well plates and grown for 24 h. Testosterone and 17β-estradiol (Sigma 
Aldrich) were added to the cells at the appropriate concentration, while only pure ethanol 
(0,00001%) was added to the control group. Cells were grown at 37 °C in 5% CO2 and 
95% air for 24 h. Cells for mRNA expression analysis were lysed directly in the culture 
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dish adding 1 mL of TRIzol reagent (Invitrogen). For microRNA expression the cells 
were collected by trypsin digestion followed by centrifugation. 
 
2.4 RNA extraction and cDNA syntheses 
 
Total RNA was isolated with TRIzol reagent, according to the manufacturers’ 
recommendations. Extracted RNAs were quantified by NanoDrop 2000 
Spectrophotometer (Thermo Fisher Scientific) and the absorbance ratio at 260/280 and 
260/230 were measured to assure RNA purity. The integrity of RNAs were controlled by 
1% agarose gel electrophoresis. 
First strand synthesis of mRNAs was carried out using SensiFAST cDNA Synthesis Kit 
(Bioline, Trento, Italy), following the manufacturer’s protocol. The reactions were 
incubated for 10 min at 25°C for primer annealing, for 15 min at 42°C to allow the reverse 
transcription and for 5 min at 85°C to inactivate the reaction. 
For cDNA synthesis of miRNAs, cells were resuspended in 1X PBS, lysed by heating at 
95°C for 5 min, and immediately chilling on ice before aliquoting 5 µl directly into 
reverse transcription reactions, as described by Chen et al., 2005. Total RNA was reversed 
transcribed using the TaqMan MicroRNA Reverse Transcription kit (Thermo Fisher 
Scientific Milan, Italy) according to the manufacturer’s protocol. The reactions were 
incubated at 37°C for 45 min to perform the poly(A) tailing reaction, and at 65°C for 10 
min to stop the reaction. Samples were then incubated at 16°C for 60 min to allow the 
adaptor ligation reaction, for 15 min at 42°C to allow the reverse transcription and 5 min 
at 85°C to stop the reaction. All cDNAs were stored at -20°C until qRT-PCR assay. 
 
2.5 Quantitative real-time PCR (qRT-PCR) 
 
Following the reverse transcription step, cDNAs were amplified in fluorescence-based 
real-time polymerase chain reaction (RT-PCR) to determine gene and miRNA expression 
levels. The qPCR assays were performed in CFX Connect Real-Time System (Bio-Rad), 
using the SensiFAST SYBR no-rox Kit (Bioline, Trento, Italy) for mRNA expression 
analyses, and using TaqMan Universal Master Mix II, no UNG, and specific TaqMan 
probes (Thermo Fisher Scientific Milan, Italy) for miRNA expression analyses. Primers 
used for mRNA qPCR are shown in Table 1a. The probe used for miRNA are shown in 
Table 1b. The amplification reactions for mRNAs expression analyses were performed 
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by an enzyme activation step of 20 sec at 95°C, followed by 40 cycles of amplification 
which were performed as following: denaturation for 1 sec at 95°C and annealing and 
extension for 20 sec at 60°C. The amplification reactions for miRNAs expression analyses 
were performed following the 7500 fast system according to the following thermos 
cycling profiles: enzyme activation for 20 sec at 95°C, followed by 40 cycles of 3 sec at 
95°C for the denaturation step, and 30 sec at 60°C for annealing and extension steps. Each 
experiment included a no-template control. Each measurement was carried out in 
triplicate in at least three different experiments. 
Normalization of gene and miRNA expression was performed using the most stable 
reference gene (as described in 3.1.3). 
 
 
Table 1a: Primers used for the analysis of mRNA expression. 
 
Gene Forward and reverse primer (5’ -> 3’) Product (bp) 
PTGS2 TGAAACCCACTCCAAACACA 198 
AGGAGAGGTTAGAGAAGGCT 
RNASEL CAGGATCTGCAACCACAAAA 82 
CCCACTTGATGCTCTTATCAAA 
 
 
 
Table 1b: Probe used for the analysis of miR expression. 
 
miRNA Assay ID 
(Applied Biosystem) 
Sequence 
hsa-miR-146a-5p 478399_mir UGAGAACUGAAUUCCAUGGGUU 
 
 
 
2.5.1 Reference gene evaluation 
 
Nine candidate reference gene and eight candidate miRs were tested as possible qPCR 
normalizers. Primers and probes used are described in Table 2a/b. 
The stability of each candidate mRNA and miRNA expression was statistically analyzed 
with three algorithm-based tools: ΔCt method (Silver et al., 2006), Best-Keeper (Pfaffl et 
al., 2004) and geNorm (Vandesompele et al.,2002). The final ranking was calculated 
applying the geometric mean of the ranks obtained from the three methods analyzing the 
expression of each gene. 
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Table 2a. Primers used for the analysis of candidate mRNA reference genes. 
 
Gene Forward and reverse primer (5’ -> 3’) Product (bp) 
GAPDH 
TGACACTGGCAAAACAATGCA 
103 
GGTCCTTTTCACCAGCAAGCT 
HPRT1 
TGACACTGGCAAAACAATGCA 
94 
GGTCCTTTTCACCAGCAAGCT 
HSD11B1 
AAGCAGAGCAATGGAAGCA 
108 
GAAGAACCCATCCAAAGCAA 
IL1R1 
AGAGGAAAACAAACCCACAAGG 
106 
CTGGCCGGTGACATTACAGAT 
POLR2K 
TTTCCGTGCTGTGTAGGG 
95 
TGTGACACTCTCCACAGA 
PPIA 
CAGGTCCTGGCATCTTGTCC 
182 
TTGCTGGTCTTGCCATTCCT 
TBP 
TGTATCCACAGTGAATCTTGG 
102 
ATGATTACCGCAGCAAACC 
TLR4 
AAATTTCCGCTTCCTGG 
109 
TCAGCCCATATGTTTCT 
YES1 
TGTGAAACCTCAGACTCAAGG 
119 
TCCATGTTCCCATCCACA 
 
 
 
Table 2b. Probes used for the analysis of candidate miRNA reference genes. 
 
 
miRNA 
Assay ID 
(Applied Biosystem) 
 
Sequence 
hsa-miR-15b-5p 478313_mir UAGCAGCACAUCAUGGUUUACA 
hsa-miR-20a-5p 478586_mir UAAAGUGCUUAUAGUGCAGGUAG 
hsa-miR-22-5p 477987_mir AGUUCUUCAGUGGCAAGCUUUA 
hsa-miR-106a-5p 478225_mir AAAAGUGCUUACAGUGCAGGUAG 
hsa-miR-128-3p 477892_mir UCACAGUGAACCGGUCUCUUU 
hsa-miR-191-5p 477952_mir CAACGGAAUCCCAAAAGCAGCUG 
hsa-miR-199a-5p 478231_mir CCCAGUGUUCAGACUACCUGUUC 
U6 snRNA 4427975 Not available from the provider 
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2.6 Statistical analysis 
 
Gene expression was calculated using the method described by Plaffl.168 Unlike the delta-
delta Ct calculation method, which assumes primer efficiencies are similar (usually 
between 90 – 110%) between the gene of interest (GOI) and the housekeeping gene 
(HKG), Plaffl calculate relative gene expression data accounting for differences in primer 
efficiencies for increasing reproducibility. 
 
The ‘E‘ in the equation refers to the primer efficiency. 
Differences in gene expression were analyzed by Student’s t test. 
2.7 Plasmid constructs 
 
The pLightSwitch + entire 3’UTR PTGS2 was purchased from SwitchGear Genomics by 
Istituto Nazionale Tumori, Milan. The entire 3’UTR region of the RNASEL was 
amplified from genomic DNA using the TransStart FastPfu DNA polymerase (Carlo 
Erba) with primer Forward and Reverse, which introduce a Xba I restriction site at the 5’ 
end of both primers. The amplified fragment was cloned in PGL3 promoter vector. 
Through these constructs we were not been able to evaluate if the genes are direct targets 
of the miR-146a probably because the 3'UTR of both genes inhibits their expression by 
many different elements. For this reason, we amplified a part of 3’UTR of both genes 
containing the binding site for miR-146a. 
To generate constructs with a reduced 3’UTR region of the PTGS2 and RNASEL, the 
recombined plasmids, containing the entire 3’UTR were amplified using the TransStart 
FastPfu DNA polymerase, with primers that, like above, introduce a Xba I restriction site 
at the 5’ end of primer forward and Sla I restriction at the 5’end of the primer reverse for 
PTGS2, and primers which introduce a Xba I site in both primers for RNASEL. The 
primers used for amplification and the length of the fragments obtained are reported in 
Table 3. Plasmid vectors were constructed by ligation of the amplified products to the 
respective empty plasmids (PLS+3’UTR_PTGS2, figure 5a and 
PGL3_PV+3’UTR_RNASEL, figure 5b). The correct direction of the insert fragment in 
PGL3 promoter vector was determined by digestion of the construct with Hind III 
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restriction enzyme (Neb cutter) which give three bands of 3844, 1949 bp when inserted 
in the correct direction and fragments of 3585 and 2208 bp when inserted is in the 
opposite direction. All plasmid constructs were confirmed by sequence analysis (BMR 
Genomics, Padova, Italy). 
Plasmids were mutagenized using primers that deleted 5 nucleotides predicted to bind the 
seed region (nt2–8) of the miR-146a by QuikChange Site-Directed Mutagenesis Kit 
(Stratagene) (PLS+3’UTR_PTGS2_MUT and PGL3_PV+3’UTR_RNASEL_MUT). 
Primers used for mutagenesis are reported in Table 3. 
 
 
 
Table 3. Primer used for the genomic amplification and mutagenesis of plasmids containing the 3’UTR of 
PTGS2 and RNASEL. 
 
Gene Forward and reverse primer (5’ -> 3’) Product 
(bp) 
PTGS2 
(reduced) 
AGATCAGAGTTCACTTTCTT 494 bp 
GTGTTTAAGCCTACAATCAT 
PTGS2 
(mutagenesis) 
CTTTCTTATTTAAAAACAAAACCAAATGATATCTAAGTACAGCAATAATAATAATGACG 
AT 
489 bp 
ATCGTCATTATTATTATTGCTGTACTTAGATATCATTTGGTTTTGTTTTTAAATAAGAAAG 
RNASEL 
(entire) 
CCTTCTAGAAACAAGCCTCAGTGTGATGG 1771 bp 
GGATCTAGACCAGGTGCTCATTACAAATC 
RNASEL 
(reduced) 
CCTTCTAGAAACAAGCCTCAGTGTGATGG 783 bp 
GGATCTAGAACCAAAAACTTCTTCAGACTC 
RNASEL 
(mutagenesis) 
ATGACCTTAAGGCAGTACAACTGGGGGGCAATTT 778 bp 
AAATTGCCCCCCAGTTGTACTGCCTTAAGGTCAT 
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Figure 5a/b: a) pLightSwitch plasmid used for the construction of a plasmid containing a part of the 3’UTR 
of the PTGS2. b) PGL3 promoter vector used for the construction of a plasmid containing a part the 3’UTR 
of the RNASEL. 
 
 
 
2.8 Transfections 
 
 
2.8.1 MicroRNAs transfection 
 
Hundred thousand (100.000) HaCaT, primary fibroblast and melanoma cells were seeded, 
in their appropriate mediums, in a 6 well plate. After 24 hours, 50 nM of miR- 146a mimic 
were transfected and cells were incubated for another 24 hours. MiR-146a mimic 
(SIGMA, Aldrich) were transfected into the three skin cultured cells using Metafectene 
(Biondex). Cells were harvested and resuspended in 1mL TRizol for RNA extraction. 
PTGS2 and RNASEL genes expression was analyzed as previously described. 
 
2.8.2 Determination of Inhibitor concentration 
 
Hundred thousand (100.000) HaCaT cells in 6 well plate were seeded in the Dulbecco’s 
modified Eagle’s medium (DMEM). After 24 hours, different concentrations (1M, 10nM, 
50nM, 100nM) of miR-146a inhibitor (antimiR; SIGMA, Aldrich) were transfected. 
PTGS2 and RNASEL genes expression and miR-146a expression were analyzed as 
previously described. 
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2.8.3 Plasmid transfections 
 
Transient transfection of the recombined vectors was performed using Lipofectamine 
3000 (Invitrogen), according to the manufacturer’s instructions. 
One hundred and thirty thousand (130.000) HaCaT cells were seeded in each well, in 24 
well plate. After 24 hours, 5ng of pLightSwitch + reduced 3’UTR_PTGS2 plasmid 
construct together with 500ng of PGL3 promoter vector (as normalizer), or 1000ng of 
PGL3 + reduced 3’UTR_RNASEL construct together with 50pg of empty pLightSwitch 
(as normalizer) were transfected. After 24 hours, the cells were lysed with Passive Lysis 
Buffer (Promega), and the relative luciferase activity was assessed with the Dual- 
Luciferase Assay Reporter System (Promega). 
 
2.9 Western blotting 
 
Seven thousand five hundred (750.000) cells were seeded in T25 flasks and incubated 
with DMEM or RPMI supplemented 10% FBS and 2mM L-glutamine and 
penicillin/streptomycin (100 U/ml and 100 µg/ml, respectively). 
After treatments with sex hormones (Testosterone 1 µM, 17β-estradiol 500 nM), HaCaT, 
primary fibroblast and melanoma cells were washed with ice PBS and then scraped and 
lysed in RIPA buffer (50mM Tris, 150mM NaCl, 1% Nonidet P-40, 0.5% sodium 
deoxycholate, 0.1% SDS) and a mixture of protease inhibitors (Mirus Bio). Cell lysis 
were carried out on ice for 30 min and then centrifuged for 20 min at 4°C, at 16.000rpm. 
Total protein concentration in cell lysates was determined by detergent compatible (DC) 
Bradford Assay analysis (Thermo Fisher Scientific). Cellular proteins were separated in 
SDS polyacrylamide 10% gel electrophoresis (SDS page) and transferred to PVDF 
membrane (Thermo Fisher Scientific) by a wet electrophoretic transfer method 
(Molecular Cloning: A Laboratory Manual, J. Sambrook, E.F. Fritsch, T. Maniatis). 
Membrane was blocked in TBS solution containing 5% non-fat milk and 0.1% Tween20 
(Merck) and then incubated overnight at 4°C with primary antibodies (Rabbit COX-2 
polyclonal antibody and Rabbit RNase-L polyclonal antibody (Wuhan Fine Biotech Co) 
diluted 1:2000 and 1:10.000 in blocking buffer. The next day, membranes were washed 
three times in 0.1% Tris, 0.2% NaCl, 0.001% Tween 20, and then were incubated with 
anti-rabbit HRP-conjugated secondary antibody diluted 1:6000 (COX-2) and 1:4000 
(RNase-L) in the blocking solution for 1h at room temperature. Signal detection was 
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accomplished using enhanced chemiluminescence (ECL, Advansta). Images were 
acquired with Azure C300 Processing machine (Azure Biosystem). Normalization of 
proteins expression was performed using β-actin. Densitometry analysis of western blot 
protein bands was carried out using the ImageJ software. Each measurement was carried 
out in triplicate in at least three different experiments. 
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3 RESULTS 
 
 
 
3.1 Quantitative real-time PCR (qRT-PCR) 
 
 
3.1.1 Candidate reference genes expression 
 
The expression of nine candidate RGs for mRNA normalization (GAPDH, HPRT1, 
HSD11B1, IL1R1, POLR2K, PPIA, TBP, TLR4 and YES1) and eight for miRNA 
normalization (U6 snRNA, miR-15b-5p, miR-20a-5p, miR-22-5p, miR-106a-3p, miR-
128-3p, miR-191-5p, and miR-199a-5p) was tested. Specifications of each candidate 
reference gene are reported in Table 4. 
 
Table 4. Function of the Reference gene analyzed in this study. 
 
 
 
Ct values of each candidate RG in HaCaT cells, fibroblasts, and melanoma cells in the 
presence or absence of hormone treatment was determined. The box-plot show the 
distribution of Ct values of each candidate gene (Figure 6). Across all the cell cultures the 
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most abundant mRNA resulted the PPIA gene; the least abundant was the HSD11B1 
(Figure 6a). MiR-15b-5p was the highest expressed in melanoma cells, U6 snRNA was 
the highest expressed in fibroblast and in HaCaT cells. MiR-199a-5p was the lowest 
expressed miRNA in HaCaT cells and fibroblasts, and miR-20a-5p was the lowest 
expressed in melanoma cells (Figure 6b). 
 
 
 
 
Figure 6: Box-plot of the quantification cycle (Ct) values for each mRNA and miRNA candidate reference 
gene. The line across the box represents the median. The box specified the 25% and the 75%. 
 
 
 
3.1.2 Gene stability 
 
Three algorithm-based tools were applied to establish the stability of coding genes and 
miRNA: ΔCt method, geNorm, and Best-Keeper. The stability ranking of the mRNA and 
of miRNA RGs is reported in Table 4. The ΔCt method consists in the quantitative 
comparison of the ΔCt variability of pairs of reference genes. The stability of each gene 
is quantified as the average standard deviation over the pairwise comparisons. The values 
showing an average of the standard deviation STDEV > 1 were excluded from the 
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analyses. Applying the ΔCt method, in HaCaT cells the analyses showed that PPIA and 
TBP are the most stable mRNAs (Table 5a). TBP resulted the most stable gene also in 
fibroblasts and in melanoma cells (Table 5b/c). The analyses of miRNA stability showed 
that miR-20a-5p and miR-191-5p are the most stable genes in HaCaT cells (Table 4d). 
The high stability of miR-191-5p expression was also demonstrated in the fibroblasts 
(Table 5e) and in the melanoma cells (Table 5f). 
The second algorithm, the geNorm program, calculates the M stability value, which is an 
average pairwise variation between all the genes under investigation, providing a ranking 
of the tested genes. The M values of all the assessed candidate genes included in the 
analyses showed a value under 1.5 that indicates a stable expression. The most stable 
mRNA indicated by geNorm was TBP in all the three cultured cells (Table 5a/b/c). In 
HaCaT cells, PPIA has the same value of TBP (Table 5a). MiR-191-5p resulted the most 
stable miRNA in both HaCaT cells (Table 5d) and fibroblasts (Table 5e); miR-128-3p 
was the most stable in melanoma cells (Table 5f). 
The third method, the Best-Keeper algorithm, developed by Pfaffl et al, uses an Excel- 
based application to determine the most stable gene, by calculating the STDEV, from a 
panel of up to ten candidate genes. The best reference genes have the lowest standard 
deviation. Reference genes with STDEV > 1 are considered not stable and were excluded 
from the analyses. Beside Ct standard deviation, the Best-Keeper considers the Best-
Keeper index (geometric mean of Ct values for each sample across all genes) in order to 
calculate the correlation coefficient value (r). Genes showing “r” values close to 1.0 
represent the most stable genes. The correlation coefficient showed that TBP is the most 
stable gene across all the three cultured cells (Table 5a/b/c). The analyses of miRNAs 
identify miR-15b-5p as the most stable in both HaCaT cells and melanoma cells (Table 
5d/f), and miR-128-3p the most stable in fibroblast cells (Table 5e). MiR- 106-3p was 
excluded from the analyses in fibroblasts due to its low expression. 
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Table 5a/b/c/d/e/f. Stability ranking of mRNA RGs analyzed by ΔCt, geNorm and Best-Keeper. 
 
 
  
 
 
  
 
  
 
  
 
(-) not included in the analysis 
c  
a d 
b e 
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3.1.3 Candidate RGs final ranking 
 
The stability measurements calculated by ΔCt, geNorm and Best-Keeper methods were 
combined to define the final ranking of each mRNA and miRNA, in the three skin cell 
types. The final ranking was calculated applying the geometric mean of the ranks obtained 
by the three methods for each gene (Figure 7). The rank-order of candidates RGs are 
represented from the least to the most stable. In HaCaT cells, PPIA and miR-191-5p 
resulted as best candidate references for the normalization of mRNA and miRNA, 
respectively. The least stable genes were HPRT1 and miR-199a-5p (Figure 7a). In 
fibroblasts, the most stable genes were represented by TBP, miR-20a-5p, miR-15b-5p and 
miR-191-5p. The least stable genes were HSD11B1 and U6 snRNA (Figure 7b). These 
analyses indicate that in melanoma cells, TBP, miR-191-5p and miR-15b-5p can be 
considered the best reference genes, whereas POLR2K and miR-22-5p may be considered 
the least stable (Figure 7c). HSD11B1 and TLR4 were excluded from the final ranking 
because of its high variability across the three tools of analyses. 
 
 
Figure 7a/b/c: Comprehensive geometric mean of the ranking values of mRNA and miRNA candidate 
reference genes calculating by ∆Ct, geNorm and Best-Keeper methods in (a) HaCaT cells, (b) primary 
fibroblasts, and (c) melanoma cells. 
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3.2 miR-146a and PTGS2 RNASEL genes expression 
 
PTGS2 and RNASEL genes and miR-146a basal expression was analyzed in primary 
fibroblasts, HaCaT and melanoma cells. The PTGS2 expression is higher in HaCaT cells 
compared to melanoma and fibroblast cells. The RNASEL expression is low in fibroblast 
and HaCaT cells and extremely low in melanoma cells. The highest expression of miR-
146a is detected in melanoma cells, much lower in HaCaT and in fibroblast. Figure 8 
reports the results. 
 
 
 
 
Figure 8: mRNAs from Fibroblasts, HaCaT and Melanoma cells were analyzed by qPCR for PTGS2 (red 
column), RNASEL (blue column) transcripts and miR-146a (green column). The results were expressed as 
relative fold change of expression levels.
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3.3 Sex hormones treatment and gene expression assay 
 
The dye exclusion test was used to determine the number of viable cells present in a cell 
suspension. It is based on the principle that live cells possess intact cell membranes that 
exclude certain dyes, such as trypan blue, whereas dead cells do not. In this test, a cell 
suspension is mixed with the dye and then microscope visualize to determine whether 
cells take up or exclude dye. No effect in cell viability was observed by the different 
concentration of sex hormones (data not showed). 
The effect of different concentration of hormones upon PTGS2 and RNASEL expression 
in HaCaT cells for 24 hours was evaluated by qPCR (Figure 9). Data analysis of real time 
PCR showed that the appropriate concentration for subsequent experiment were 1 µM for 
testosterone and 500 nM for 17β-estradiol. 
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Figure 9: Graphs show the relative genes expression determined by quantitative real-time PCR. The 
HaCaT cells were treated with different concentration of sexual hormone.  After 24 hours the PTGS2 and 
RNASEL gene expression was evaluated. In the upper graphs (in pink) =17 beta estradiol (17 β-E); in the 
lower graphs (in blue) =testosterone (T). 
 
 
Subsequently a time-point experiment was performed (0, 4, 6, 24, 48 hours) treating the 
cells with the concentration of 1 µM for testosterone and 500 nM for 17β-estradiol. 
PTGS2 and RNASEL expression was detected by qPCR (Figure 10). The results showed 
that the best incubation time for the experiments was 24 hours in both genes. 
 
 
 
 
Figure 10: Graphs show the relative genes expression determined by qPCR. The PTGS2 and RNASEL gene 
expression in HaCaT cells treated with 1 µM of testosterone and 500nM of 17 β-estradiol was evaluated 
at different times (0h,4h,6h,24h,48h). In the upper graphs (in pink) =17 beta estradiol (17 β-E); in lower 
graphs (in blue) =testosterone (T). 
 
59  
3.4 Real Time expression analyses after hormones treatments 
 
To evaluate the effect of sex hormonal (1 µM for testosterone and 500 nM for estradiol 
for 24 hours) in HaCaT, primary fibroblast and melanoma cells, qPCR for PTGS2, 
RNASEL gene and miR-146a expression were performed. The results are reported in 
Figure 11. 
In HaCaT cells, RNASEL and PTGS2 gene expressions were significantly increased 
with testosterone treatments. 17β-estradiol demonstrated no effect in the genes expression 
in these cells. The expression of miR-146a was increased with 17β-estradiol, while no 
effect of testosterone was observed. 
In melanoma cell, an increased RNASEL expression was observed after the treatment 
with 17β-estradiol. No significant result was detected with testosterone stimuli. The 
expression of PTGS2 gene remained unchanged in this cell line with both treatments. The 
expression of miR-146a was significantly increased with testosterone treatment. 17β-
estradiol demonstrate no effect in this cell line. 
In primary fibroblasts, no different in RNASEL expression was detected with either 
hormone. A significant reduction in PTGS2 expression was observed in the case of 
testosterone treatment. The expression of miR-146a appeared higher, albeit not 
significant, after 17β-estradiol treatment.
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Figure 11: Graphs show the relative gene and miR expression determined by qPCR. Expression of PTGS2, 
RNASEL and miR-146a after sex hormones treatment for 24 hours was evaluated in the three cultured cells, 
HaCaT (a), Melanoma cells (b) and Fibroblasts (c).  The blue bars indicate the treatment with the 17beta 
estradiol (17 β-E); the red bars indicate the treatment with testosterone (T); and the grey bars, EtOH, 
indicate controls with only hormones solvent (ethanol 0,00001%). 
 
 
 
3.5 Western blotting analyses after hormones treatments 
 
The effect of hormones upon COX-2 and RNase-L proteins expression were evaluated 
through western blotting analysis. The results are reported in Figure 12. 
In HaCaT cells, COX-2 protein expression was increased, although not significant, by 
testosterone treatment. 17-βestradiol significantly decreases COX-2 protein expression. 
The expression of RNase-L protein was augmented by testosterone and showed a non- 
significant decrease by 17β-estradiol treatment. 
In melanoma cells, the expression of COX-2 protein resulted up-regulated after 17- 
βestradiol treatment. Expression of COX-2 remained unchanged with testosterone 
treatment. An increase of RNase-L protein after the treatment with 17-βestradiol was 
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observed which correspond to the increased in mRNA expression. Testosterone had an 
opposite effect, decreasing RNase-L protein expression. 
In primary fibroblasts the expression of COX-2 and RNase-L proteins remained 
unchanged with both treatments.
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Figure 12: Western blot analysis of COX-2 and RNase-L after 24 hours treatment with 17-beta estradiol 
(17 β-E) or testosterone (T) in HaCaT, Melanoma and Fibroblast culture cells. The quantification of the 
amount of COX-2 and RNase-L was calculated relative to the amount of β-actin.  
 
 
 
3.6 Effects of miR-146a transfection upon PTGS2 and RNASEL expression. 
 
HaCaT, melanoma and primary fibroblasts cells were transfected with mature synthetic 
miR-146a at 50 nM concentration for 24 hours. Real Time PCR showed that transfection 
of mimic-146a showed no significative effect upon the expression of the genes at the used 
concentration. In figure 13 a/b/c the results are represented.
1
7
-β
 E
st
ra
d
io
l 
C
o
n
tr
o
l 
T
es
to
st
er
o
n
e 
β-Actin 
COX-2 
RNase-L 
63  
 
 
Figure 13: Graphs show the relative gene expression determined by qPCR. Cells were transfected with 
50nM miR-146a. After 24 hours cells were harvested and the expression of PTGS2 and RNASEL was 
assessed in HaCaT, melanoma and fibroblast culture cells. The green bars indicate the gene expression 
after miR-146a transfection, the grey bar indicate the control.  
 
 
3.7 Inhibitor concentration effects upon miR-146a expression 
 
The expression of PTGS2, RNASEL and miR-146a was evaluated by real time PCR. 
Concentrations of 50 nM and 100 nM of inhibitor reduced the expression of miR-146a 
demonstrating its functionality (Figure 14c). mRNA expression of both genes was not 
modified by the different inhibitor concentrations indicating that miR-146a is not 
affecting the genes transcription or stability. (Figure 14 a/b). Further western blot analysis 
are necessary to determine if miR-146a effects the translation of the coded proteins.
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Figure 14 a/b/c: Graphs show the relative gene and miR expression determined by qPCR. Different 
concentrations of inhibitor of miR-146a (1nM, 10nM, 50nM, 100nM) were transfected in HaCaT cells. 
After 24 hours, PTGS2 (a), RNASEL (b) and miR-146a (c) expression was determined. Controls were 
treated only with the transfection reagent. 
 
 
 
3.8 Effect of miR-146a on reporter protein activity 
 
To determine whether miR-146a directly regulates PTGS2 through its 3′ UTR, luciferase 
reporter assays were performed in HaCaT cells. The cells were transfected with empty 
pLightSwitch plasmid (PLS), or plasmid with part of the 3’UTR encompassing the 
miRNA binding site (PLS+3’UTR_PTGS2); or with the corresponding mutated plasmid 
(PLS+3’UTR_PTGS2_MUT). Transfections with PLS+3’UTR_PTGS2 down-regulated 
the relative luciferase reporter activity. The down-regulation of the luciferase activity was 
unaltered or even lower when transfecting the mutated PLS+3’UTR_PTGS2_MUT, 
indicating that in keratinocytes, PTGS2 is not a direct target of miR-146a. (Figure 15) 
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Figure 15: The graph shows a relative activity of luciferase after 24 hours transient transfection in HaCaT 
cells. The plasmids that were transfected in keratinocyte cells are pLightSwitch (first column), 
pLightSwitch+3’UTR_PTGS2 (second column) and pLightSwitch+3’UTR_PTGS2_MUT (third column). All 
plasmids were transfected also with PGL3 promoter vector (as normalized).   
 
 
 
3.9 Direct interaction of miR-146a with the RNASEL 3’UTR 
 
To assess the specificity of miR-146a to regulate RNASEL expression through its 3’UTR, 
luciferase report assays were performed, in figure 16 are reported the results.  
HaCaT cells were transfected with the recombinant plasmid containing part of the 3’UTR 
encompassing the miRNA binding site (PGL3_PV+3’UTR_RNASEL) or with the 
corresponding mutated plasmid (PGL3_PV+3’UTR_RNASEL_MUT). A Significant 
down-regulation in relative luciferase reporter activity was observed in response to 
PGL3_PV+3’UTR_RNASEL construct. The mutated corresponding plasmid restored in 
part the activity of the luciferase. 
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*P value = 0,04 
 
Figure 16: The graph shows a relative activity of luciferase after 24 hours transient transfection in HaCaT 
cells. The plasmids that were transfected in keratinocyte cells are PGL3 promoter vector (first column), 
PGL3+3’UTR_RNASEL (second column) and PGL3+3’UTR_RNASEL_MUT (third column). All plasmids 
were transfected also with pLightSwitch (as normalized).   
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4 DISCUSSION 
 
Growing evidences are showing gender-associated functions playing a role in cancer 
incidence, progression and response to therapy.169 Different studies showed the female 
advantage in several different cancer types.169 Representative examples of gender 
disparities have been associated with colorectal cancer, urothelial and kidney cancer170 as 
well as melanoma.171 
Although female sex is associated with a survival advantage in several cancer types, 
studies in both Europe and United States showed that this advantage was considerably 
higher in melanoma than in virtually any other type of cancer. Since the late 1960s, Clark 
observed that cutaneous melanoma was more aggressive in men.172 More recently, 
according to EUROCARE4 data, melanoma was reported to display the most significant 
female advantage in survival of patients.173 
Nonetheless the protective factors are still unknown. Although the source of gender 
disparity in melanoma remains unclear, two main hypotheses for female advantage can be 
offered: 1) differences in behavior and 2) unknown biologic sex differences.174 Looking 
for the underlying molecular mechanisms, tumor itself does not appear to be different 
across gender as confirmed by several studies showing no differences in mutation rates of 
some important genes in melanoma, most notably in the BRAF gene. However, several 
host factors, which differ across gender have been linked to melanoma progression and 
survival and might therefore offer an explanation for the female melanoma advantage. 
These include hormone levels (estrogens and androgens,), the immune system, autophagy, 
matrix metalloproteinase-2, skin physiology, vitamin D, obesity and reactive oxygen 
species. In fact, all these molecules and biological processes have been hypothesized to 
display sex disparities.169 The genetics of melanoma is intricate, in addition to the several 
well documented gene mutations that have been associated with development of 
melanoma175, considerable attention is being focused on the participation of epigenetic 
events. The interplay between epigenetic events affects the regulation of transcriptional 
and/or translational activities. The epigenetic events involved in initiation and progression 
of melanoma may be aberrant methylation of the promoter regions, histone modification, 
chromatin remodeling, and the positioning of nucleosomes.176 As epigenetics factors, 
microRNAs (miRs) are considered as important elements regulating gene expression 
involved in initiation, promotion and progress of melanoma.177 Gender difference in miRs 
expression have been described in peripheral blood, brain and colon rectal mucosa178, in 
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lung adenocarcinoma, and other cancers.179 
The interaction of different cells and micro environmental factors are involved in the 
development of melanoma; cell growth, differentiation, apoptosis and migration are 
mediated by cell to cell crosstalk. For example, a switch of the developing tumor from the 
inhibitory interaction with keratinocytes to interact with host fibroblasts results in 
uncontrolled proliferation and invasion of the malignant cells.180/181/182/183 
Keratinocytes are important players in melanoma development since they control growth, 
morphology, and antigen expression of normal melanocytes through cell-cell 
contact.182Among the different functions, these cells protect from the skin by UV rays 
which are the major risk factor for the development of melanoma. 184 Exposure of the skin 
to UV produces inflammation characterized by erythema185 and edema and may promote 
tumor formation. As well, UVB irradiation has been shown to induce the formation of free 
radicals and deplete cellular antioxidant stores.186/187 Data presented by Miller et al.188 
indicate that UVB induces tyrosine kinase activation by oxidative injury, which results in 
increased prostaglandin synthesis by cyclooxygenase-2 (COX- 2). COX-2 plays a major 
role in modulating the inflammatory properties observed in UVB-irradiated skin and in 
UVB-induced experimental tumors.189/190 COX-2 is strongly expressed in malignant 
melanoma and may be correlated with the development and progression of disease.191/192 
Sex differences in prostaglandins production (PGs) have been described in many 
inflammation-related diseases193/194/195, such as response to peritonitis, pleurisy, mumps 
virus infections, autoimmune and chronic diseases. For instance, in cystic fibrosis, severe 
asthma, or chronic pulmonary obstructive disease females showed a poorer prognosis 
compared to males.193 
In the present study, we observed different sex hormone effects upon PTGS2/COX-2 
expression depending on the cells analyzed. An augmented expression of COX-2 and its 
coding gene PTGS2 was observed in keratinocytes upon testosterone treatment, while 
17β-estradiol upregulates COX-2 in melanoma cells. Considering the potential role of 
inflammation in tumor initiation and promotion, our results suggest that PTGS2/COX-2 
could be involved in gender bias in the incidence of melanoma through its higher 
expression and transduction in males. In melanoma cells, the upregulation of COX-2 by 
17β-estradiol may play an anti-inflammatory role by generating other set of anti- 
inflammatory PGs in females, and thus, participating in the better rate of survival.196/197/198 
The down-regulation of PTGS2 in fibroblasts upon testosterone was not significantly 
observed in COX-2 protein expression suggesting an effect of testosterone on PTGS2 
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mRNA stability.199 
Ribonuclease-L (RNase-L) is known to be a ubiquitous enzyme involved in several 
cellular functions, especially in innate immunity. It is an established mediator of IFN 
antiviral and antiproliferative activities that functions as the terminal component of an 
RNA decay pathway. The cell growth inhibitory and proapoptotic effects of RNase led to 
the assumption that RNase-L could be a tumor suppressor gene196/200, by inhibiting 
oncogenic viruses, but also through its pro-apoptotic and cell growth inhibitory properties. 
As such, it is possible to speculate that higher expression of RNASEL can have a 
protective effect upon tumorigenesis. 
In the present study, we observed an augmented expression of RNase-L and its coding 
gene RNASEL in melanoma cells after treatment with 17β-estradiol and a diminished 
expression of RNase-L protein under testosterone. The cell growth inhibitory and pro- 
apoptotic effects of RNase-L suggest that higher expression of RNASEL can have a 
protective effect upon tumor progression and could participate in the survival advantage 
in females. The results obtained in keratinocytes showed an increase of RNase-L 
expression as a result of testosterone treatment. This augmented expression of RNASEL 
could represent an attempt to attenuate androgen signaling which has been demonstrated 
to promote cancer progression by inhibiting apoptosis or by promoting cell survival or 
proliferation.201 
MicroRNAs (miRNAs) can contribute to human cancer predisposition by regulating the 
genetic expression of proto-oncogenes or tumor suppressor genes. High levels of miR- 
146a has been reported in melanoma tissue and cell lines202/203, and its role as oncogene 
has been discuss in several studies.204/205 Consistent with these observations, our data 
showed a very high expression of miR-146a in melanoma cells compared with its 
expression in HaCaT and fibroblast cells. Testosterone induced an even greater increase 
expression of miR-146a in melanoma cells. This effect can represent a disadvantage in 
males since augmented expression of miR-146a can interfere, among others, with the 
STAT1/ IFN-γ axis which reduced cell-migration, cell cycle activity, and basal oxygen 
consumption rate in melanoma cells206/203 and by activating Notch signaling that promoted 
primary melanoma progression.207 
On the other hand, 17β-estradiol increases the expression of miR-146a in keratinocytes, 
suggesting that it could represent a protective factor for females by controlling 
inflammatory genes in these cells. The dual role of miR-14a have been reported in 
different diseases. For example, in keratinocytes, miR-146a may contribute to reduce 
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excess inflammatory responses after exposure to microbial agents208 and it can direct target 
members of the NF-kB signaling helping to fine-regulate the immune response.209 In 
prostate cancer, miR146a has demonstrated to be a tumor suppressor by targeting 
regulators of many cellular processes, including the cell cycle, cell-cell adhesion, motility, 
and of epithelial differentiation.210 
In summary, the hormonal environment influences miR-146a expression, gene and protein 
expression of PTGS2 and RNASEL differently depending on the skin cell type. The up-
regulation of PTGS2/COX-2 in keratinocytes upon testosterone treatment indicates the 
possible participation of this gene/protein as a risk factor for males regarding the initiation 
and promotion of melanoma. On the other hand, the up- regulation of RNASEL/RNase-L 
in melanoma cells by 17β-estradiol suggest that RNASEL may play a role in the better 
rate of survival in females. The upregulation of miR-146a expression may represent a risk 
factor for males in melanoma cells participating in tumor progression whereas it can have 
a protective role in females by inhibiting inflammatory processes in keratinocytes. In 
conclusion PTGS2, RNASEL and miR-146a sex hormonal responses, suggest that both 
genes and miR-146a could participate in the gender bias in melanoma. 
 
The relation between PTGS2, RNASEL and miR-146a 
 
An interaction of RNASEL with miR-146a have been associated to melanoma211 and to 
non-melanoma skin cancer risk.212 In a similar way, a polymorphism in the promoter 
region of PTGS2 together with a SNP in miR-146a showed an association to melanoma 
risk (manuscript in preparation). Both genes present binding sites for miR-146a. Based on 
this information, we investigated the eventuality miR-146a regulation upon PTGS2 or 
RNASEL 3’UTR genes expression in keratinocyte cells. 
The regulation of PTGS2 is complex and many elements have been recognized that 
modulate mRNA translation, mRNA stability, and translational regulation.213 Among 
them, binding site for different miRs are located in the 3’UTR that could regulate 
translation and stability of the gene.214 
The direct regulation of PTGS2 by miR-146a has been validated in lung cancer93 and in 
human gastric epithelial cells.215 Nevertheless, if a particular miRNA-target is validated in 
a specific tissue type, the same interaction may not be true in a different tissue. Indeed, 
through transfection in keratinocyte cells of a recombinant vector containing part of the 
3’UTR of PTGS2, we were not able to demonstrate that PTGS2 is a direct target of miR-
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146a as the mutagenized vector showed an even less luciferase activity than the one 
containing the binding site for the miR. 
The expression of RNASEL must be tightly regulated since it mediates critical cellular 
functions including antiviral, pro-apoptotic, and tumor suppressive activities.113 The 
regulatory function of the 3’UTR of the gene has been tested in different cell lines; it 
contains multiple candidate AREs, and sequential deletion of these elements identified 
positive and negative regulatory regions.216 Regulation of RNASEL has been mainly 
investigated in prostate carcinogenesis (Pca), where several differentially expressed 
miRNAs between PCa and adjacent benign tissues obtained from PCa patients have been 
identified.217 
There is no scientific data demonstrating the interaction of miR-146a with RNASEL. Only 
one study has shown that RNASEL is a direct target of the miR-146b (miR-146b differs 
from miR-146a by having two different nucleotides at its 3'-end) in rat cardiomyoblast 
cell line.218 
From our expression and transfection data, it can be state, that the putative miR-146a- 
binding site is a functional site as part of the regulation of RNASEL, although probably 
its participation in the post-transcriptional regulation of the gene does not play a main role. 
In fact, in vitro analysis in all three skin cells did not show an effect of miR-146a upon the 
RNASEL gene or protein expression. Nevertheless, deletion of the miRNA- binding site 
resulted in a partial restore of luciferase activity demonstrating that RNASEL is a direct 
target of miR-146a in keratinocytes. 
In conclusion in HaCaT cells, miR-146a targets RNASEL with a probably minor effect 
on its regulation. This direct interaction was not observed in PTGS2 gene. 
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